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Bone mineral density (BMD) is a macro-scale measurement used to diagnose osteoporosis and 
assess treatment efficacy, but it cannot capture nanoscale alterations within bone microstructures 
where fracture initiates.  The objectives of this research were to determine variations in tissue 
properties within the microstructures of cortical and cancellous bone with aging, osteoporosis, 
and treatment, and examine their effects on microcrack resistance and mechanical function at 
higher length scales.   
First, changes in tissue properties with the natural ageing process were examined in a 
baboon model for human ageing.  Tissue stiffness and hardness followed trends in mineralization 
and aligned collagen content with animal age, increasing sharply during growth and remaining 
constant after sexual maturity.   
Once this baseline for the natural ageing process was established, osteoporosis and 
antiresorptive treatment effects on bone tissue properties were examined in an ovine model for 
human osteoporosis.  Zoledronate, from the most widely prescribed class of osteoporosis drugs 
(bisphosphonates), was compared with a treatment that acts through endogenous estrogen 
receptor pathways in bone, raloxifene (a selective estrogen receptor modulator, SERM).  
zoledronate was most effective in cancellous rather than cortical tissue and provided the greatest 
increases (relative to osteoporotic tissue) in stiffness, hardness, and mineralization at trabecular 
surfaces.  In comparison, increases in these properties with raloxifene were similar throughout 
cancellous and cortical tissue.  Both treatments improved the estimated bending stiffness of 
individual trabeculae, possibly providing some explanation for the large reductions in fracture 
risk with these drugs despite minimal changes in BMD.  At higher length scales, zoledronate 
 improved bending stiffness and failure moment in whole bone tests.   
Finally, microcracking resistance was assessed via a newly-developed experimental 
technique.  The reduced resistance to crack elongation in cortical tissue from the osteoporosis 
model was largely corrected by raloxifene.  These results suggest that bisphosphonate/SERM co-
treatment treatment could possibly combine the best aspects of both drugs—the rapid 
improvement in strength with zoledronate and the improved microcrack resistance with 
raloxifene.  The nanoscale alterations in bone tissue documented in this thesis provide a better 
understanding of normal and pathological bone function and may enable development of 
improved therapies for the prevention and treatment of osteoporosis. 
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CHAPTER 1 
INTRODUCTION 
 
Ageing and age-related skeletal diseases such as osteoporosis lead to fragility fractures that 
compromise the skeleton’s ability to provide structural support for the body.  One in three 
women and one in five men over the age of fifty will experience an osteoporotic fracture in their 
lifetime [1–3].  Fragility fractures lead to increased morbidity and mortality, and the associated 
economic burden is over $17 billion dollars annually in the United States, alone [4]. 
 
1.1 Osteoporosis Diagnosis and Bone Mineral Density 
Osteoporosis is diagnosed by measuring bone mineral density (BMD) with a dual-energy x-ray 
absorptiometry (DEXA) scan.  Patients with BMD between 1 and 2.5 standard deviations below 
the mean for a young, healthy adult (T-score of -1 to -2.5) are diagnosed as osteopenic, or having 
low bone density.  Patients with BMD more than 2.5 standard deviations below the young adult 
mean (T-score < -2.5) or who are osteopenic and have fragility fracture are diagnosed as 
osteoporotic.  Patients with BMD more than 2.5 standard deviations below the young adult mean 
with a fragility fracture(s) present are deemed severely osteoporotic [5].   
 Bone is a hierarchical composite material with factors from the sub-nanoscale through the 
scale of the whole bone contributing to fracture risk (Figure 1).  BMD measures the quantity of 
bone and the overall level of mineralization at the apparent (bulk tissue) level, but cannot resolve 
alterations in properties at smaller length scales.  Failure in bone initiates at these smaller length 
scales and depends on tissue micro-architecture, nanoscale properties of mineral and matrix 
constituents, and spatial distributions of mineral and matrix properties within bone structures [6–
17].  Discrepancies between BMD and fracture risk highlight the importance of considering 
property alterations below the apparent level:  1) BMD alone is relatively insensitive to first 
fracture risk.  Clinically, large overlaps in BMD exist between groups of patients with and 
without fractures, and patients with identical BMD t-scores have different fracture outcomes 
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[8,18–20].  Fractured and non-fractured patients show differences in tissue composition and 
organization at the micro- and nanoscales [6,21–23].  2) Antiresorptive treatments for 
osteoporosis provide large reductions in fracture risk (30-50%) despite only minor changes in 
BMD (0-8%) [11,24,25].  Tissue from treated patients shows micro and nanoscale alterations in 
mineral and matrix properties, heterogeneity, microdamage, and tissue architecture [26–34].  3) 
Previous fluoride treatments for osteoporosis increased BMD but did not reduce fractures.  
Abnormal mineral formation and mineralization defects caused by fluoride treatment impair 
mechanical function [35–40].  
Clearly, contributions from all hierarchical length scales in bone must be considered to 
fully understand mechanisms of bone fragility and successfully develop and evaluate new 
therapies.  Most studies to date focus on apparent or whole bone length scales; therefore, micro 
and nanoscale alterations in tissue composition and organization with ageing, disease, and 
treatment must be documented and related to alterations visible at these higher length scales.  
 
1.2 Bone Composition and Microstructure 
The organization within bone extends across multiple length scales (Figure 1).  The tissue itself 
Figure 1.1  Hierarchical structure of bone across multiple length scales.  Figure adapted from [45]. 
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is a mineral-platelet-reinforced composite comprised of 65% mineral, 35% organic matrix, cells, 
and water [41–43].  The mineral phase is an impure form of hydroxyapatite, Ca10(PO4)6(OH)2 
with incorporated ions such as carbonate, citrate, magnesium, fluoride, and strontium.  The 
organic matrix is roughly 90% Type I collagen and 10% noncollagenous proteins and serves as 
the template for mineralization [41,44].  Sub nanoscale triple-helical collagen molecules 
assemble together in highly ordered, staggered arrays to form fibrils.  These arrays are stabilized 
by collagen cross-links.  Plate-shaped crystals nucleate in gap zones between collagen molecules 
and extend into overlapped regions between molecules.  The mineral crystals orient with their 
long axis (c-axis) parallel to the longitudinal axis of the fibrils [41,42,44,45].  These fibrils 
bundle together to form collagen fibers, which in turn form layers called lamellae. 
The healthy human skeleton contains two distinct tissue microarchitectures:  a dense 
architecture called cortical bone, and a more porous structure called cancellous bone.   Cortical 
bone forms the exterior shell of the skeleton and is prevalent in the midshafts of long bones.  
Cancellous bone is interior to the cortical shell and is found primarily in vertebrae and at the 
ends of long bones [41,44].  In both cortical and cancellous bone, highly-aligned, mineralized 
collagen fibers form layers called lamellae.  Lamellae in cortical bone form concentric cylinders 
around longitudinal blood vessels and create the basic structural unit called the osteon [41,44].  
The collagen orientation between successive lamellae in cortical bone is thought to rotate in a 
plywood-like fashion [46–49].  The structure of cancellous bone is less dense than cortical bone 
and consists of rod and plate-like struts called trabeculae.  Lamellae form roughly parallel to the 
long axes of the individual struts [41,44].  The alignment of collagen within cancellous lamellae 
is less documented, though evidence suggests that the collagen fibers are preferentially oriented 
along the longitudinal axes of trabeculae [50].  Between lamellae in both cortical and cancellous 
bone are transition zones called interlamellar regions.  These regions appear to have less aligned  
or less dense collagen and are less mineralized than the lamellae, though the exact nature of 
interlamellar regions is still unclear and somewhat controversial [51,52]. 
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1.3 Modeling and Remodeling 
As a living, biological material, bone continuously adapts to surrounding conditions.  Through 
modeling and remodeling, bone responds to changes in the loading environment, repairs 
microdamage, and maintains ion homeostasis within the body [41,44].  Due to the constant 
turnover of bone tissue, a single bone will contain tissue of varying ages.  The variety of tissue 
ages within bone structures leads to microscale and sub microscale heterogeneity in both 
composition and mechanical properties, and specific spatial distributions of these properties 
within bone structures [53–63].     
 The modeling and remodeling processes are performed by bone cells:  osteoclasts are 
responsible for the resorption (removal) of bone tissue, while osteoblasts lay down 
unmineralized osteoid (predominantly collagen) that then undergoes mineralization.  Osteocytes 
(osteoblasts that become embedded in the bone matrix) are also involved in modeling and 
remodeling by serving as a sensory network that detects strain and possibly microdamage in 
bone tissue and then acts together with bone lining cells to direct the timing and location of 
modeling and remodeling events [41,44,64].   
Modeling in human bone occurs predominantly during growth prior to skeletal maturity 
but can also occur in response to mechanical stimulation throughout life.  In modeling, 
osteoclasts and osteoblasts are decoupled and resorption and formation can occur independently 
and on different bone surfaces [41,44].  During growth, formation primarily adds bone to the 
periosteal (outer) surfaces while resorption removes bone (more slowly) from the endosteal 
(inner) surfaces.  The modeling process is also responsible for shaping the ends of long bones. 
The remodeling process maintains the bone structure—replacing immature (primary) 
bone in infancy and older, damaged bone throughout life.  Remodeling removes microdamage, 
replaces dead or over-mineralized bone, and maintains mineral homeostasis in the body.  During  
remodeling, osteoclasts and osteoblasts are closely coupled through signaling factors and 
resorption and formation are spatially related and occur in a cyclic manner [41,44,65]. 
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1.3.1 Remodeling in Cortical Bone 
The osteonal structure of cortical bone forms as a result of the remodeling process, which takes 
place along canals containing blood vessels running longitudinally through the bone (Figure 2).  
Osteoclasts tunnel along these blood vessels, called Haversian canals, and resorb cylindrical 
volumes of bone.  Osteoblasts follow and deposit layers of unmineralized bone matrix called 
osteoid to refill the volume, starting at the periphery and finishing at the center blood vessel.  
The resorption phase is relatively short in comparison to the formation phase and lasts one to two 
weeks.  The resorption cavity is refilled and the surface near the blood vessel again becomes 
quiescent two to four months after the process began [41,44,66].  The resulting osteon contains a 
natural gradient of increasing tissue age from center to periphery because of the way the 
cylindrical volume was filled back in from periphery to center [59].   
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Figure 1.2  Diagram of the Haversian remodeling process with the distance and time scale measured 
from the tip of the cutting cone (A).  The remodeling event in this figure is traveling from right to left.  
(B) Osteoclasts resorb existing bone.  (C) Dividing precursors of osteoclasts and osteoblasts.  (D) 
Capillary loop.  (E) Mononuclear cells lining the reversal zone from resorbing to forming.  (F) Cement 
line separating new from old bone.  (G) Osteoblasts forming layers of new bone.  (H) Osteoid.  (I) Cells 
lining the Haversian canal after remodeling process is completed.  Figure adapted from [66]. 
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1.3.2 Remodeling in Cancellous Bone 
Cancellous bone is more metabolically active than cortical bone due to the high surface-to-
volume ratio and proximity to blood and marrow [41,44].  The basic structural unit is the 
trabecular packet, an irregularly-shaped volume of bone that is removed and replaced from the 
trabecula during the remodeling process (Figure 3).  Remodeling units in cancellous bone travel 
along surfaces of trabeculae.  Osteocytes remove a wedge-shaped volume of bone and are 
followed by osteoblasts that refill the space with osteoid [41,44,66].  Like in cortical bone, the 
remodeling process in cancellous bone creates a natural gradient in tissue age.  The youngest 
tissue is at the surfaces of trabeculae where the osteoblasts finished refilling the resorption 
cavity.
Figure 1.3  Diagram of the trabecular remodeling process.  The remodeling event is traveling from 
right to left in this figure.  Time points one and two show resorption by osteoclasts; time point three 
shows reversal; time points four and five show formation by osteoblasts, and time point 6 shows the 
completion of remodeling with the new surface covered with lining cells.  Figure adapted from [66]. 
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1.3.3 The Mineralization Process and Mineral Heterogeneity 
The mineralization process progresses in two phases once the unmineralized osteoid is laid down 
by osteoblasts.  In the first 5-10 days after formation the tissue rapidly accrues up to 70% of final 
mineralization in the phase called primary mineralization.  The rate of mineral accrual 
subsequently slows in the secondary mineralization phase [41,66–69].  Levels of mineral content 
follow the spatial variations in tissue age due to the time-dependency of the mineralization 
process.  Consequently, newly formed osteons in cortical bone are less mineralized than the older 
interstitial tissue between osteons [53].  The osteons themselves contain an increasing gradient in 
mineralization following the gradient in tissue age from center to periphery [21,70].  In 
cancellous bone, newly formed trabecular packets are less mineralized than older, more mature 
packets.  Newer tissue at the surface is less mineralized than older tissue nearer the center of the 
trabeculae [56,71,72]. 
 
1.4 Apparent Level Structure-Mechanical Function Relationships 
Mechanical testing of machined bulk tissue specimens demonstrates that the collagen matrix in 
bone primarily provides toughness while the mineral-platelet reinforcement provides stiffness.  
Degradation of bone’s collagen matrix with irradiation while leaving the mineral phase intact 
substantially reduces work to fracture and impact energy but has little effect on stiffness (Figure 
4) [73,74].  Conversely, progressive decalcification to remove mineral without disrupting the 
collagen matrix decreases stiffness while leaving post-yield behavior unchanged (Figure 4) [75].  
Though bone mineral dominates elastic behavior, more highly-mineralized bone supports less 
strain at failure [42].  The collagen matrix is crucial for post-yield toughness and gives the bone 
composite an order of magnitude greater failure strain than that provided by the mineral alone 
[42,74,76]. 
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1.4.1 Effects of Heterogeneity and Spatial Variations on Nanomechanical Function 
More recently, nanoscale mechanical tests paired with compositional analyses show that tissue 
stiffness and hardness follow trends in mineralization [56,59,62,68,77,78].  These 
nanomechanical properties also increase with greater aligned collagen content [79].  Nanoscale 
spatial distributions and biological heterogeneity in tissue composition cause similar 
nanomechanical property variations in bone tissue [62].  Tissue stiffness and hardness increase 
rapidly in the first days after formation with the process of primary mineralization and then level 
off in older tissue with the slower progression of secondary mineralization [67,68].  Osteons in 
human cortical bone have lower stiffness and hardness than older, more mineralized interstitial 
tissue [53,54,62,80].  Similarly, newer trabecular packets have lower stiffness and hardness than 
older trabecular packets within human cancellous bone [56,63,72].  In both cortical and 
cancellous tissue, nanomechanical properties fluctuate between lamellar and interlamellar 
regions.  Lamellar tissue has greater stiffness and hardness than interlamellar tissue due to 
greater mineral and aligned collagen content [53,54,62,79,80].  Fracture toughness below the 
Figure 1.4  (Left) The effect of irradiation on four mechanical properties of human compact bone.  
Irradiation degrades collagen while having little impact on mineral.  Samples with degraded collagen 
had decreased work to fracture (decreased toughness) and decreased impact energy, yet had little 
change in Young’s modulus (stiffness).  Figure from [74]. (Right) Yield stress, ultimate stress, and 
elastic modulus vs. the amount of calcium removed in bovine tensile bone specimens.  R
2
 values range 
from 0.94 to 0.98.  Figure from [175]. 
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apparent level is difficult to measure experimentally, and consequently has not been correlated 
with these variations in nanoscale tissue composition and mechanical properties. 
 
1.4.2 Effects of Nanoscale Tissue Variations on Macro-Scale Mechanical Function 
The contribution of nanoscale mechanical property variations to changes in macro-scale 
mechanical function and fracture risk remains largely unclear.  Modeling studies in cortical bone 
suggest nanoscale mechanical heterogeneity (especially in inelastic properties) promotes energy 
dissipation in the bulk tissue [15,16].  Transverse cracks arrest or deflect at interfaces between 
osteons and the interstitial tissue between osteons, trapping cracks at the cement lines and 
providing a mechanism for slowing crack growth and increasing fracture toughness [81–83].  A 
conflicting view is that cortical bone microstructure exists primarily for the improved ability to 
remodel and remove microdamage.  Proponents of this theory suggest the Haversian 
microstructure actually reduces resistance to fatigue relative to a more uniform structure [84,85].  
Nonetheless, variations between osteonal and interstitial properties affect microcrack 
propagation and direction [86].  Increasing ratios of interstitial to osteonal hardness correlate 
experimentally with decreased longitudinal fracture toughness [87].   
Failure of cancellous bone results from the microdamage and failure of individual 
trabecular struts [88–90].  Struts transverse to the primary loading direction fracture first due to 
shear stresses induced from a cantilever-type mode of bending.  Struts aligned in the primary 
loading direction subsequently fail by buckling.  Both transverse and longitudinal trabeculae 
dissipate energy by accumulating microscopic internal matrix damage prior to failure [88–90].  
Modeling of heterogeneity in trabecular bone demonstrates that the regions of lower stiffness at 
surfaces alter distributions of stress and strain within trabeculae and may result in greater stress 
magnitudes when compared to a simplified homogeneous model [12]. 
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1.5 Ageing and Osteoporosis 
The primary cause of osteoporosis is a loss of estrogen with ageing [91,92], though other factors 
such as disuse, estrogen-independent age-related mechanisms (such as hyperparathyroidism, 
oxidative stress in bone cells), certain drugs, also contribute to bone loss [91,93].  Osteoporosis 
is more prevalent in women because they have lower bone mass than men and experience 
precipitous bone loss at menopause with the abrupt loss of estrogen (Figure 5) [92].  Estrogen 
regulates both the rate of bone turnover and the balance between resorption and formation in the 
remodeling cycle [93–95].  A negative balance develops when estrogen is lost and less bone is 
formed than resorbed in each remodeling cycle.  Coupled with an increased activation frequency 
of remodeling cycles, this imbalance causes the rapid drop in bone mass associated with high-
turnover or postmenopausal type I osteoporosis in women.    
 
 Estrogen’s action in bone is complex and mediated by a host of factors that directly and 
indirectly affect bone remodeling cells [93,96–99].  With estrogen loss, the rate of remodeling 
increases, osteoclastogenesis increases and apoptosis decreases, and osteoblastogenesis and 
osteoblast apoptosis increase.  Hence, greater numbers of osteoclasts with prolonged activity 
resorb larger than normal volumes of bone in each remodeling cycle.  Concomitantly, increased 
Figure 1.5  Schematic showing bone mass with age in humans.  Women experience a precipitous drop 
in bone mass at menopause resulting from the abrupt loss of estrogen [97]. 
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numbers of osteoblasts are unable to keep up with resorption due to decreased lifespan and 
consequently a negative balance develops.  
 
1.6 Osteoporosis Treatment 
Current treatments for osteoporosis employ two strategies for combating increased turnover and 
the loss of bone mass with estrogen withdrawal [25,100–105].  To date, most treatments are 
antiresorptive and target osteoclasts.  These drugs inhibit the total amount of bone turnover, 
including both resorption and formation.  In contrast, new anabolic agents employ an alternative 
approach and increase only bone formation.  Effects of treatments can differ between skeletal 
sites, cortical and cancellous bone, and patient populations [106,107].  Drugs are approved by the 
Food and Drug Administration (FDA), and can be approved for prevention and/or treatment of 
osteoporosis [5].  For approval to prevent osteoporosis, i.e. to prevent the decline in bone mass 
with menopause, treatments must improve BMD but not necessarily reduce fracture risk in a 
population without osteoporosis.  For approval to treat postmenopausal osteoporosis, i.e. to 
correct the loss of bone once it has already initiated, treatments must significantly reduce fracture 
risk among postmenopausal women.   
Calcium and vitamin D are crucial in preventing and treating osteoporosis in addition to 
pharmaceutical interventions [100,105].  Vitamin D is essential for calcium absorption from the 
gut.  Deficient levels of vitamin D and/or calcium cause hyperparathyroidism—excessive 
secretion of parathyroid hormone (PTH) from the parathyroid glands due to hypocalcaemia—and 
osteomalacia—poorly mineralized bone.  Consequently, bone resorption increases to compensate 
for the calcium deficiency by removing calcium from the bone [108,109].  Vitamin D and 
calcium supplements are most effective in elderly populations who often do not receive adequate 
vitamin D from diet and sunlight exposure [100,110–112].  Supplementation is less effective or 
ineffective in populations with adequate intake and populations with less-deficient levels [113].  
These studies suggest that deficiencies should be corrected, but calcium and vitamin D are not  
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sufficient to treat osteoporosis [100,105].  Adequate calcium and vitamin D levels also maximize 
the effectiveness of pharmaceutical treatments [114]. 
 
1.6.1 Antiresorptive Agents 
Antiresorptive drugs are divided into several subclasses, each acting through different 
mechanisms to decrease bone turnover and reduce fracture risk.   These subclasses include 
hormone replacement therapies (HRT:  estrogen, estrogen + progestin), selective estrogen 
receptor modulators (SERMs:  tamoxifen and raloxifene), bisphosphonates (alendronate, 
zoledronate, risedronate, ibandronate, etc.), non-steroidal hormones (calcitonin), and antibodies 
(denosumab).  Hormone replacement therapies are approved only for prevention of osteoporosis.  
Raloxifene and the bisphosphonates are approved for both prevention and treatment, and the 
non-steroidal hormones are approved for treatment only [115]. 
 
1.6.1.1   Hormone Replacement Therapy 
HRT has fallen out of favor due to a controversial benefit/risk profile [116,117].  Women who 
have had a hysterectomy can receive estrogen alone, while women with an intact uterus receive 
estrogen and progestin in a combined cyclic regimen [100].  These therapies increase the risk for 
deep vein thrombosis and pulmonary embolism, and there is some evidence that long term 
treatment may increase cancer risk (breast, endometrial, and ovarian) [100,105,107,118].   
HRT increases BMD and reduce fracture risk by simply replacing the estrogen that is lost 
with menopause (see section 1.5).  BMD increases 5-10% in early, late, and elderly 
postmenopausal populations, with the most marked reductions in women who began therapy 
within five years after menopause [100,105].  Estrogen reduces vertebral, non-vertebral, and hip 
fractures by roughly 30% compared with placebo [100,105,107,118].  The addition of progestin 
does not alter the bone effects of estrogen [105,118].  Unfortunately, bone loss resumes after 
treatment cessation and progresses at the same rate as prior to treatment [100,105,107,119–121].  
Within five years of treatment withdrawal, the reduction in fracture risk is lost regardless of 
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treatment duration [119–121].  The long term benefit/risk profile and bone loss post-treatment 
raise questions about treatment efficacy and whether HRT benefits outweigh the risks.   
 
1.6.1.2   Selective Estrogen Receptor Modulators (SERMs) 
SERMs have an advantage over HRT because they exhibit tissue-specific agonist-antagonist 
activity.  Thus, they can mimic the effects of estrogen in bone (see section 1.5) and reduce bone 
turnover, but not stimulate tissues in which the effects of estrogen are undesirable (endometrium, 
breast).  The two SERM treatments most investigated for osteoporosis treatment are tamoxifen 
and raloxifene.  Only raloxifene has obtained FDA approval because tamoxifen is a weak agonist 
for bone and increases cancer risk by stimulating the endometrium [100,122].  Raloxifene is a 
stronger agonist in bone, reduces the risk for breast cancer, and does not increase the risks for 
cardiovascular events, uterine bleeding, or endometrial cancer like HRT [100,118,122].  Similar 
to HRT, raloxifene can increase the risk for venous thrombosis and may also increase hot flashes 
[100,122]. 
SERMs act through endogenous estrogen pathways to reduce bone turnover and fracture 
risk.  These drugs bind to estrogen receptors (ER-α and ER-β) and act through estrogen response 
elements (EREs) and coregulator proteins.  The effects of raloxifene on bone turnover and 
fracture risk are relatively well documented.  Raloxifene prevents bone loss at all skeletal sites 
(vertebral, hip, and non-vertebral) and reduces bone turnover markers to premenopausal levels in 
early postmenopausal women [100,122].  Vertebral fractures are reduced by 30-50%, depending 
on dosage, but hip or non-vertebral fractures are not significantly decreased [100,122].  Despite 
the marked reduction in vertebral fracture risk, three years of raloxifene treatment increased 
BMD by only 2% in the spine and proximal femur [122].  Like HRT, bone loss resumes after 
raloxifene treatment cessation[123]. 
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1.6.1.3 Bisphosphonates 
Bisphosphonates are the largest and most studied class of drugs and act as the first line of 
treatment for postmenopausal osteoporosis.  The first generation of bisphosphonates does not 
contain nitrogen, has limited potency, and is not approved by the FDA.  Newer, nitrogen-
containing bisphosphonates are much more potent and several have FDA approval for prevention 
and treatment:  alendronate, risedronate, ibandronate, and zoledronate [114,124–126].  The 
safety profile of bisphosphonates is better than that of HRT. The most common side effects are 
mild gastrointestinal irritation that can become severe in some patients [100,105,107,124].  
Intravenously administered zoledronate and ibandronate produce no gastrointestinal effects.  In 
rare cases, bisphosphonates have been associated with osteonecrosis of the jaw; however, most 
of these patients were treated with high doses for cancer [93].  Bisphosphonates stay 
metabolically active in the body for decades after administration and bone turnover markers 
remain reduced for at least five years after treatment cessation [93,127].  Rare cases of atypical 
femoral fractures with long-term bisphosphonate treatment have been reported, although the 
precise mechanisms behind this phenomenon are yet unknown [124,128].  Recent concerns have 
arisen that long-term bisphosphonate treatment may result in over-suppression of bone turnover 
and impairment of the skeleton’s ability to repair microdamage [106,114,124].   
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The chemical structure of nitrogen-containing bisphosphonates dictates skeletal uptake 
and retention and determines the relative potency of the various compounds (Figure 6) 
[114,125].  Flanking phosphate groups on either side of the central carbon atom provide a high 
affinity for bone mineral and allow binding to hydroxyapatite crystals.  The R
2
 side-chain 
determines potency.  Bisphosphonates preferentially bind to bone mineral at sites of active bone 
remodeling (Figure 6) [114]. When endocytosed by osteoclasts during resorption, 
bisphosphonates prevent osteoclast fiber assembly and membrane ruffling and osteoclast 
apoptosis ensues [114,126].  Simultaneously, the activation frequency of new remodeling units 
formed by osteoclasts is reduced and the rate of turnover decreases [114,126].  With less 
frequent bone turnover, the duration of secondary mineralization is extended and a greater 
percentage of bone tissue reaches high levels of mineralization [26,114,129,130].  In addition to 
Figure 1.6 (A) Bisphosphonate chemical structure showing R
2
 side chains.  (B) Side chain structure of 
nitrogen-containing bisphosphonates and their associated potency [114]  . (C) Bisphosphonates bind to 
bone mineral and are taken up by osteoclasts during resorption [176]. 
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endocytosis by osteoclasts, a low level of bisphosphonates is continuously released from the 
bone and activates survival kinases that promote osteoblast survival [131].  Consequently bone 
formation is increased despite the overall reduction in bone remodeling.  This produces a slight 
increase in BMD, from 0-8% [25,132].   
All approved bisphosphonates except for ibandronate provide marked fracture reduction 
at vertebral, hip, and non-vertebral skeletal sites [107,114].  Ibandronate reduces vertebral 
fractures but has not substantially reduced fractures at other sites.  Reductions in fracture rates 
are similar between alendronate, risedronate, and zoledronate:  40-65% in vertebral, 30-55% in 
hip, and 20-60% in non-vertebral fractures in large population studies [93,118].  Out of these, 
alendronate and zoledronate produce the greatest increases in BMD (Figure 7) [107,124].   
Fractures are reduced in osteopenic and osteoporotic women and those with or without vertebral 
fractures [93,124].  Alendronate, the most studied bisphosphonate (and indeed the most studied 
osteoporosis drug), continues to reduce bone turnover at least five years after cessation of 
treatment [124].  Alendronate and zoledronate have a more prolonged effect after treatment 
withdrawal than risedronate and ibandronate [124] likely due to their higher affinity for bone 
mineral. 
Figure 1.7  Improvement in BMD with approved bisphosphonate treatments for the lumbar spine, total 
hip, and femoral neck..  Different colors on the bars show effects of different treatment durations.  
alendronate and zoledronate provide the greatest increases in BMD.  These data also illustrate the 
variation in treatment effects between different skeletal sites [124].   
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1.6.1.4   Calcitonin 
Though approved by the FDA, the use of calcitonin for treating postmenopausal osteoporosis has 
been limited by cost and poor tolerance.  Side effects were common with subcutaneous and 
intravenous injection and included nausea, flushing, and diarrhea [100,105,133].  Tolerance 
improved with the development of an intranasal delivery system; however, some patients still 
develop neutralizing antibodies that render calcitonin ineffective [105].  Furthermore, calcitonin 
is much less potent than other treatments, reduces vertebral but not non-vertebral fractures, and is 
less effective at preventing cortical than cancellous bone loss [100,105,107,118].  Calcitonin is a 
second or third line drug for patients who cannot tolerate bisphosphonates [133].   
Calcitonin is a amino-acid peptide hormone produced by thyroid C cells that binds to 
calcitonin receptors on osteoclasts and rapidly inhibits osteoclast activity [100,105,133–135].  
Osteoclasts lose their ruffled border and motility, and the proton pump and excretion of 
lysosomal enzymes are inhibited [135,136].  The resulting reduction in vertebral fractures is 
about 30%, with little effect on BMD [107,118].   
 
1.6.1.5 Denosumab 
Denosumab is a promising new treatment for osteoporosis recently approved by the FDA for 
patients at high risk for fracture [106].  Indications for treatment are osteoporosis with either a 
history of osteoporotic fracture, multiple risk factors for fracture, or intolerance to other 
treatments.  The safety profile through three years of use is excellent [137].  Concerns to be 
studied are the long-term effects both on the immune system and due to osteoclast suppression 
[106]. 
Denosumab is a fully human monoclonal antibody to RANKL.  RANKL is produced by 
osteoblasts and is a local factor that regulates osteoclast differentiation.  By binding to RANKL 
and preventing binding with RANK (receptor activator of nuclear factor-κβ) receptors on cells of 
the osteoclast lineage, denosumab reduces osteoclastogenesis, osteoclast activity, and hence bone 
resorption [137–139].   
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Denosumab reduces turnover to a greater degree than bisphosphonate treatment and 
reduces vertebral, hip and non-vertebral fractures [106].  Vertebral fractures were reduced by 
68%, hip fractures by 40%, and non-vertebral fractures by 20% in large clinical trials [140,141].  
Forearm BMD also increases with denosumab, demonstrating potency in both cortical and 
cancellous bone [137].  In contrast, bisphosphonates do not affect forearm BMD.  Denosumab is 
not incorporated into bone tissue like the bisphosphonates and is cleared rapidly after treatment 
withdrawal [106,141].  Thus, improvements in bone turnover markers and BMD are lost when 
treatment is stopped.  However, reintroduction of denosumab again reduces turnover markers 
and increases BMD [137].   
 
1.6.2 Anabolic Agents 
Only one anabolic agent, teriparatide (hPTH [1-34]), is currently approved by the FDA for 
treatment of postmenopausal osteoporosis.  While the antiresorptive treatments decrease bone 
turnover (both resorption and formation), anabolic treatments increase bone turnover and 
stimulate osteoblasts more than osteoclasts.  With each remodeling cycle resorption spaces are 
overfilled causing a net increase in bone mass [106,142–144].  Anabolic treatments may even 
decouple osteoblasts and osteoclasts and stimulate formation directly without requiring prior 
bone resorption [143].  Trabecular thickness and connectivity increase with anabolic treatments; 
in contrast, antiresorptive treatments only stabilize and preserve trabecular architecture 
[143,144]. 
Clinical trials were performed with both recombinant human parathyroid hormone (rhPTH 
[1-84]) and synthetic human parathyroid hormone (teriparatide, hPTH [1-34]).  The FDA 
rejected rhPTH [1-84] due to side effects of hypercalcemia and hypercalcinuria (high levels of 
calcium in the blood and urine, respectively) and clinical trials were abandoned due to 
development of osteosarcoma (malignant bone tumors) in rats [100,141,142].  The rates of 
osteosarcoma were dose and duration dependent [143].  Teriparatide gained FDA approval, but 
only for treatment of patients at high risk for fracture or who did not respond to other treatments.  
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Treatment duration is approved only to 24 months due to the safety concerns, and the expense of 
teriparatide is relatively high compared to other osteoporosis treatments [100].  
Endogenous human PTH is an 84-amino acid peptide secreted from the parathyroid glands.  
The intact peptide and its fragments (including teriparatide) are key endocrine regulators of 
calcium homeostasis and act as either anabolic or catabolic agents in bone, depending on the 
manner of administration [144,145].  Continuously high levels of PTH in pathologic conditions 
such as primary hyperparathyroidism or chronic renal disease result in bone loss, whereas 
intermittent administration builds bone mass.  The anabolic response of teriparatide is mediated 
through a host of factors.  Teriparatide acts through PTH/PTHrP receptors found in osteoblasts, 
osteocytes, and bone lining cells [96,145,146].  With teriparatide, osteoblastogenesis increases 
and osteoblast apoptosis is prevented [145,146].  With more osteoblasts that live longer, 
remodeling sites are over-filled and there is a net gain in bone.  In addition, bone lining cells 
revert to an active osteoblast phenotype and modeling is renewed at key sites such as the 
periosteum [145].  Through these effects on cells in the osteoblastic lineage, intermittent PTH 
administration rapidly increases the level of bone formation [145,147].  Eventually, the increase 
in formation is followed by a delayed and smaller increase in bone resorption.  This delay creates 
the “anabolic window”—the time period in which anabolic treatment is most effective [145,147]. 
Figure 1.8  The anabolic 
window created by intermittent 
PTH administration.  Bone 
formation is rapidly increased 
while the increase in resorption 
is delayed [106]. 
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Teriparatide markedly reduces both vertebral and hip fracture risk.  Vertebral fractures 
are reduced by over 60% and non-vertebral by over 50% [118].  Remarkably, moderate to severe 
fractures are reduced by 90% [145].   The average increase in BMD with 1-3 years of treatment 
is 10-14%, due to improvements in the trabecular compartment [143,144].  Both trabecular 
thickness and connectivity increase with treatment [143,144].  In contrast, cortical BMD is not 
improved or decreases slightly due to increased endocortical remodeling [143].  Though the 
resulting increase in cortical porosity initially raised concern, increased cortical diameter and 
thickness due to periosteal apposition appear to compensate biomechanically [143].   
Improvements in BMD and fracture risk are greater with teriparatide than with 
Alendronate, but BMD gains are lost when teriparatide is withdrawn [142,143].  Micro-
computed tomography-based models also show greater increases in vertebral strength with 
teriparatide than with alendronate relative to controls [148].  Combination therapies with 
antiresorptive treatments are being studied as a way to preserve improvements in BMD and 
fracture risk.  Combination treatment with either HRT or raloxifene improves BMD in 
postmenopausal women over mono-therapy, and combination treatment with denosumab 
performed similarly in rats [142,144,147].  Treatment with alendronate subsequently to 
teriparatide provides additional gains in BMD [143,145,147].  In contrast, pre-treating with 
bisphosphonates blunted the effects of teriparatide [93,142,143,145,147]. 
  
1.6.3 Treatments in Development 
Antiresorptive and anabolic drugs in the development pipeline show promise for future 
prevention and treatment for postmenopausal osteoporosis.  Several new SERMs—bazedoxifene, 
lasofoxifene, ospemifene—are in stage III clinical trials [141].  Bazedoxifene shows similar 
effectiveness as raloxifene at reducing vertebral fractures.  The strontium salt, strontium ranelate 
is also in stage III clinical trials and is already approved in Europe.  Strontium substitutes for 
calcium ions in bone mineral and exerts a combined anabolic and antiresorptive effect, 
rebalancing bone turnover in favor of formation [100,101,105,106,149,150].  The reduction in 
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fractures with strontium ranelate is more modest than that with bisphosphonate treatment.  
Vertebral fractures are reduced by roughly 40% and non-vertebral fractures by 15% [150].  
 
1.7 Apparent Level Mechanical Effects of Osteoporosis and Treatment 
To date, apparent level and nanoscale characterization of bone with osteoporosis and treatments 
has been limited and has focused on effects in cancellous tissue because fragility fractures occur 
in predominantly cancellous locations.  However, the cortical shell becomes increasingly 
important for load bearing and fracture resistance with the preferential loss of cancellous bone 
with osteoporosis [40,91,151–153].  Treatment differences may also exist between cortical and 
cancellous tissue [154].  Thus, in the future cortical tissue should also be considered when 
evaluating osteoporosis and the success of potential therapies.   
At the apparent level, micro-CT based modeling of bone from patients with and without 
fragility fractures shows that patients with fractures have a cancellous architecture that is 
overadapted to the primary loading axis [155,156].  Patients with fractures have decreased 
transverse stiffness but no change in stiffness or strength in the primary loading direction 
compared to patients without fractures [155,156].  With SERM treatment, cancellous and cortical 
bone had increased primary stiffness, strength, and toughness in a canine model relative to 
healthy control animals [157].  Bisphosphonates also increase cancellous stiffness in the primary 
loading direction relative to untreated, healthy canines [23]. 
 
1.8 Nanoscale Compositional and Mechanical Effects of Osteoporosis and Treatment 
Increased turnover and imbalances in the remodeling cycle with osteoporosis result in nanoscale 
compositional and mechanical alterations in bone tissue.  To date, studies of nanoscale property 
changes with osteoporosis have produced mixed results because of small sample sizes 
[58,154,155,158–160].  In cancellous bone, osteoporosis reduces the overall heterogeneity of 
both tissue mineralization and mineral crystallinity within trabeculae [58,155,159,160].  Patients 
with fragility fractures demonstrated increased mineralization and mineral crystallinity compared 
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to those without fracture [21].  Increased mineralization is beneficial for strength and stiffness up 
to a point, but excessive mineralization can lead to brittleness [21].  Decreased work to fracture 
with ageing correlates with decreased work to fracture of the collagen network and increased 
pentosidine cross-links formed during nonenzymatic glycation [161]. Collagen maturity was also 
elevated in fractured patients and the spatial distribution of collagen maturity within trabeculae 
was markedly altered [21,22].  
 Few studies have characterized alterations in nanoscale tissue material properties with 
treatments, and even fewer have correlated treatment-induced changes in composition with the 
resulting effects on tissue nanomechanical function and crack resistance.  Most of these studies 
only examined changes in cancellous tissue.  Additionally, most tissue-level studies have been 
performed with bisphosphonates, since these drugs have been around the longest and are the 
most widely used for treatment of post-menopausal osteoporosis. 
The reduction in turnover with bisphosphonates results in fewer new remodeling packets 
with lower levels of mineralization and a greater proportion of the bone reaches mature 
mineralization levels.  Human bone tissue treated with alendronate has increased mineralization 
and reduced mineral heterogeneity relative to osteoporotic bone [34,129,162].  The same has 
been shown in animal models with zoledronate treatment [26,72,163,164].  Alendronate and 
risedronate increased cancellous and cortical tissue mineralization and collagen crosslinking 
maturity and decreased mineral heterogeneity in canine studies [26,27].  Treatment effects in 
these animals differed slightly between cancellous and cortical tissue.  With bisphosphonates, 
collagen structure was altered through increased nonenzymatic (mature) crosslinks and increased 
isomerization [27].  Interestingly, in these same animals the SERM, raloxifene, did not alter 
collagen structure.   
Increasing evidence from animal models suggests that changes in tissue composition with 
osteoporosis and treatments results in alterations in tissue mechanical function and crack 
resistance.  Nanoscale tissue stiffness followed increased tissue mineralization in cancellous 
tissue from ovariectomized ewes treated with bisphosphonates [72].  Cancellous tissue treated 
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with alendronate and risedronate had increased numbers of microcracks and increased crack 
density compared to untreated tissue in the aforementioned canine studies [31].  Cortical tissue 
from the ribs of these dogs had greater crack length [165].  Increased microdamage correlated 
positively with increasing dose and treatment duration in these studies [31,165].  Interestingly, 
the treated vertebrae and ribs had similar strength as those from untreated animals when 
normalized by BMD, but had reduced energy absorption and toughness [31,165].  These studies 
provide remarkable insight into micro- and nanoscale alterations with bisphosphonate treatment; 
however, the canine model does have some limitations.  Animals were not osteopenic or 
osteoporotic and were estrogen replete.  Additionally, the rib is not load-bearing and may behave 
differently than load-bearing sites. 
Raloxifene treatment in canines also altered mechanical function with evidence pointing 
towards changes in tissue material properties as a factor.  Raloxifene enhanced vertebral strength 
independent of a change in BMD [30], suggesting that alterations in tissue properties might be a 
factor.  However, unlike bisphosphonates, raloxifene did not alter collagen structure in these 
animals [27].  In vertebral cortical bone of the rat, raloxifene increased both indentation modulus 
and hardness relative to OVX [166]. 
Like the antiresorptive treatments, the anabolic agent, teriparatide, has been shown to 
alter tissue material properties and crack resistance.  Teriparatide treatment for 24 months 
decreased crack length in iliac crest biopsies from treatment naïve patients and decreased crack 
density, crack surface density, and crack length in patients previously treated with alendronate  
[167].  In rats, teriparatide increased nanoscale tissue hardness relative to OVX in vertebral 
cortical bone [166]. 
 
1.9 Thesis Aims 
Alterations in macro-scale measures of BMD and fracture risk with ageing, osteoporosis, and 
approved treatments are well-established; however, changes in BMD account for only a small 
proportion of the changes in fracture risk.  Micro- and nanoscale alterations in bone material 
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composition and organization play an important role in the mechanical function of the skeleton 
and may explain some of the discrepancy between BMD and fracture risk.  Nanoscale alterations 
with ageing, osteoporosis, and treatments are not well documented and understanding these 
alterations will improve our ability to predict fracture and develop successful treatment. 
 
1.9.1 Aim 1:  Establish a Baseline for Nanoscale Material Alterations with Ageing 
Nanoscale material variations with the natural ageing process in healthy bone tissue must first be 
established to understand changes leading to age-related and osteoporotic fragility fractures.  
Previous studies of human bone tissue produced conflicting results with tissue age and patient 
age due to the limited age ranges of subjects studied and small sample sizes 
[53,60,62,70,168,169].  Therefore, the first objective of this thesis was to establish a baseline for 
the age-related compositional and nanomechanical alterations that occur in bone tissue with the 
natural ageing process.  Part of this aim was to correlate the changes in tissue composition with 
their resulting nanomechanical effects.  Understanding these relationships improved our 
understanding of normal bone function.   
The first experiment of this thesis work addressed the first aim by examining nanoscale 
tissue composition and nanomechanical properties in the osteons of a primate model for human 
ageing.  Human bone is difficult to obtain and data regarding health and treatment are often 
unreliable.  Baboons contain the same Haversian microstructure and remodeling process as 
human bone and females follow a very similar ageing process that includes menopause, 
reproductive senescence, and eventually skeletal fragility with ageing [170].  The baboons for 
this experiment were from a closely-monitored colony with reliable data regarding health and 
treatment and were not used for any other study; therefore, they should provide an accurate 
baseline for changes with the natural ageing process.  Material changes with tissue age were 
studied in these animals by characterizing tissue along radial lines following the gradient in 
tissue age across osteons.  Changes with animal age were investigated by examining osteons in 
bones from animals with ages spanning the entire baboon lifetime—from birth through skeletal 
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maturity and old age.  These results were presented at the Materials Research Society and 
Orthopaedic Research Society annual meetings and have been published in the Journal of 
Biomechanics [171].   
 
1.9.2 Aim 2:  Determine Nanoscale Alterations with Osteoporosis and Treatment 
Once the natural age-related variations in nanoscale tissue composition and mechanical function 
were established, pathological alterations with osteoporosis and treatments could be observed.  
Altered or imbalanced remodeling with osteoporosis and treatments can affect nanoscale 
composition and mechanical properties and spatial distributions of these properties within bone 
structures [22], yet few studies have documented changes at this length scale.  The second aim of 
this thesis was, therefore, to examine nanoscale material changes with osteoporosis and different 
treatments.  Correlating nanoscale tissue composition and nanomechanical function in this aim 
and relating changes at the nanoscale to changes at higher length scales provided a better 
understanding of pathological bone function and may eventually enable researchers to improve 
upon current therapies for skeletal disease. 
 A large, multi-level experiment was designed to address Aims 2 and 3 of this thesis.  In 
this experiment, nanoscale material properties were examined and correlated within cancellous 
and cortical bone from an ovine model for postmenopausal osteoporosis.  Spatial distributions of 
properties were characterized across individual trabecular struts in cancellous bone and 
individual osteons in cortical bone.  Alterations in cortical and cancellous tissue were compared 
because both are important for fracture resistance and treatment can produce different effects in 
different tissue types; however, few studies have examined cortical bone and there is a small 
population of patients on long-term bisphosphonate treatment that have experienced atypical 
cortical fractures [128].  In these same animals, bulk and whole bone mineral and mechanical 
properties are examined to determine how changes in nanoscale properties translate to changes at 
higher length scales.  Like the baboon model from Experiment 1, mature ovine bone contains a 
Haversian microstructure similar to human bone and health and treatment status can be closely 
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monitored and controlled [172–174].  The dietary metabolic acidosis model (MA) in ewes 
produces similar changes as postmenopausal osteoporosis and reduces both BMD and whole 
bone strength [173,174]. 
 The first treatment chosen for this experiment was a bisphosphonate because this class of 
drug is most widely prescribed and most studied.  In addition, bisphosphonates are the only 
treatments to date whose effects are maintained after withdrawal [127].  Alendronate was the 
original bisphosphonate chosen for this experiment because it is the most widely used and oldest 
of the nitrogen-containing bisphosphonates [115].  Alendronate (and zoledronate) also provides 
the greatest change in BMD and fracture risk of the bisphosphonates and prevents fracture at 
vertebral, hip, and non-vertebral sites [124].  Due to problems administering alendronate through 
cannulae in the ewes, the bisphosphonate was switched to zoledronate.  Zoledronate has a similar 
potency to alendronate and can be given intravenously, eliminating the need for cannular 
administration.   
 The SERM, raloxifene, was chosen as the treatment for comparison.  Raloxifene is the 
most potent and only FDA-approved SERM.  Zoledronate and raloxifene are both antiresorptive 
drugs that act through distinctly different mechanisms.  Both provide similar reductions in 
fracture risk in the vertebrae [107].  In addition, raloxifene acts through the natural estrogen 
pathways in bone, making it an ideal choice for comparison [99]. 
 
1.9.3 Aim 3:  Examine Micro-Cracking With Osteoporosis and Treatment 
Failure of bone initiates at the tissue-level with damage and micro-cracks.  Bisphosphonate 
treatment has been linked with increased microcracking [31,33,165], and concern has arisen that 
over-supression of bone turnover with treatment  may eventually lead to increased propensity for 
microcracking and the accumulation of damage.  Fracture resistance is difficult to measure at 
these small length scales and no one has yet examined relationships between changes in 
nanoscale tissue material properties and changes in microcracking resistance with osteoporosis 
and treatment.  Therefore, the third aim of this thesis was to develop a method to induce 
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microscale cracks in bone tissue and to examine differences in cracking with osteoporosis and 
different treatments. 
 Aim 3 was addressed by part of the large, multi-level ovine experiment outlined in Aim 
2.  A sharp tip connected to a microindentation instrument was used to create micro-cracking in 
the same cortical specimens previously used to characterize nanoscale material properties.  
Differences in the propensity for micro-cracking and micro-crack behavior are examined with 
osteoporosis, zoledronate, and raloxifene.  Differences between newer osteonal tissue and older 
interstitial tissue were also compared.   
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CHAPTER 2 
MICROSTRUCTURE AND NANOMECHANICAL PROPERTIES IN OSTEONS RELATE 
TO TISSUE AND ANIMAL AGE
*
 
 
2.1  Introduction 
The incidence of osteoporotic fracture increases dramatically with ageing [1,2].  Measures of 
bone mass and architecture alone are inadequate for predicting age-related fracture risk [3–5].  
Tissue-level material properties are a missing component in our knowledge of ageing and bone 
fragility, but are clearly critical to understanding skeletal mechanical integrity.  Nano-scale 
variability of the elastic modulus in healthy bone hinders crack propagation and acts as a 
toughening mechanism [6,7].  In addition, osteoporosis alters the nano-scale heterogeneity of the 
material properties and composition of bone tissue [8–10]. 
To understand the skeletal changes leading to osteoporosis and age-related fracture, one 
must first understand the natural variations that occur in healthy bone tissue with ageing [11].  
Due to the remodeling process, bones from a single animal contain tissue of varying ages; thus, 
tissue age within a given animal is not the same as the animal’s age.  In primates, the Haversian 
remodeling process creates a natural gradient in tissue age across the osteon [12].  In this 
process, osteoclasts travel along the Haversian canal and resorb a cylindrical volume of bone 
surrounding the blood vessel.  Osteoblasts follow the osteoclasts and form layers of bone to refill 
the resorbed cylinder, starting at the periphery and finishing at the center near the blood vessel 2 
to 4 months after the process was initiated [13].    Hence, in a section transverse to the Haversian 
canal, osteons appear as concentric ring-like structures, with the newest tissue located at the 
center nearest to the blood vessel, and the oldest tissue located at the periphery of the osteon.  
Tissue-level variations in composition and mechanical properties with either tissue or 
animal age have been studied individually, producing mixed results [14–19].  As a consequence, 
                                                 
*
 Burket JC, Gourion-Arsiquaud S, Havill LM, Baker SP, Boskey AL, van der Meulen MCH.  Microstructure and 
nanomechanical properties relate to tissue and animal age.  Journal of Biomechanics 2011; 44(2):  277-284. 
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relationships between these properties and ageing in humans are still unclear.  Even fewer 
studies have related tissue composition to mechanical function [20–22].  Furthermore, material 
variations have only been examined over limited age ranges [14,18,19,23].  As tissue 
composition plays a crucial role in determining mechanical function, understanding these 
relationships will improve our understanding of normal and pathological bone function and may 
enable us to improve upon current therapies for skeletal diseases such as osteoporosis.  In rodent 
models, tissue composition and mechanical properties varied systematically with tissue age in 
newly formed tissue [21,22]; however, cortical microstructure and skeletal ageing processes of 
rodents differ markedly from those of humans. 
The present study utilized the natural gradient in relative tissue age across osteons in 
female baboons to study tissue age and animal age-related variations in tissue composition and 
mechanical properties over the entire lifespan of the animal.  Baboon bone is an excellent model 
for human bone because baboons have a similar Haversian microstructure resulting from 
secondary remodeling and also experience a similar ageing process, including increased skeletal 
fragility [24,25].  The maximum lifespan of a baboon is approximately 1/3 that of the human, 
with sexual maturity occurring around five years of age [26,27].  This lifespan is sufficiently 
long to elicit reproductive senescence and menopause, accompanied by changes in hormone 
levels that are important in bone metabolism and loss [24,28,29].
 
The goals of this study were to characterize changes in nanomechanical properties and 
tissue composition with both tissue age (relative and animal age over the entire lifespan of the 
baboon, and to examine relationships between tissue composition and mechanical properties. In a 
previous study of the baboon samples utilized here, preliminary analyses with Raman 
spectroscopy and more extensive analyses with Fourier transform infrared spectroscopic imaging 
(FTIRI) showed variations in compositional parameters with both tissue and animal age [12].
 
 
However, variations in mechanical parameters were examined only with tissue age in one age 
group (13 years old).  We hypothesized that tissue mechanical properties would vary with 
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changes in mineral and aligned collagen content as a function of both tissue and animal age in a 
non-human primate model.  
 
2.2 Materials and Methods 
 
2.2.1 Samples and Specimen Preparation.   
Femoral bone samples were obtained from twelve female baboons examined previously [12], 
aged 0.28 to 32.45 years, representing the majority of the baboon lifespan [27].  All animals were 
housed outdoors in group housing at Southwest National Primate Research Center/Southwest 
Foundation for Biomedical Research (SNPRC/SFBR, San Antonio, TX) and had no evidence of 
metabolic bone disease.  The Institutional Animal Care and Use Committee approved all 
procedures at SNPRC/SFBR, and no animals were euthanized specifically for this study. 
 After necropsy, the femurs were wrapped in saline soaked gauze and stored at -20º C.  
The femurs were fixed, dehydrated, and embedded in polymethlymethacrylate [30].  Transverse 
sections from the midshaft were polished anhydrously to achieve a root mean square surface 
roughness less than 15 nm on a 5 μm x 5 μm AFM scan (Dimension 3100, Veeco Metrology 
Group) [31].   
 Three osteons per sample were selected for characterization by nanoindentation, Raman 
spectroscopy and SHG, and three radial lines were characterized within each osteon (Figure 2.1).  
To sample a consistent anatomical area between samples, osteons were selected from the 
postero-lateral quadrant of the femurs, within 2 mm of the endosteal surface (Figure 2.1).  The 
osteons did not have widened Haversian canals and lamella near the canals were well-formed 
and not eroded, suggesting that these osteons were not remodeling at the time of animal death.   
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Figure 2.1 (A) Cross section of a baboon femur embedded in polymethlymethacrylate showing the area 
chosen for characterization.  (B) Light microscopy image of the area boxed in part (A) with specific 
osteons chosen for characterization circled. (C)  Atomic force microscopy image of a quadrant of one 
of the osteons showing one radial line that was characterized with nanoindentation, Raman 
spectroscopy, and second harmonic generation.  The residual indentations are visible in the white 
triangles.  The insert shows a magnified view of a residual indentation. 
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2.2.2 Nanoindentation.   
Nanoindentation was used to probe the tissue nanomechanical properties.  As nanoindentation 
tests volumes of material at a length scale less than that of individual microstructural features in 
bone, this technique avoids confounding factors such as microstructure and porosity that affect 
tissue properties at larger length scales [32,33].  A 20 μm x 20 μm surface topography scan was 
made with the scanning nanoindenter (TriboIndenter, Hysitron, Inc.) prior to each indentation to 
place them at the center of lamellae, ensuring that comparable material was sampled between 
measurements (Figure 2.1) [31,34].  Each osteon contained between 5 and 15 lamellae that were 
characterized along 3 radial lines, resulting in 15 to 45 indentations per osteon (~ 45 to 135 per 
animal).  The tip was loaded into the sample at a rate of 50 μN/s, held at a maximum load of 700 
μN for 10 s, and then unloaded at a rate of 50 μN/s [31,34], resulting in ~150 nm deep 
indentations.  The indentation modulus and hardness were calculated from the unloading portion 
of the load-displacement curve [35].   
 
2.2.3 Raman Spectroscopy  
 Raman spectroscopy was used to characterize the tissue composition.  Spectra were 
collected using a near-infrared, 785 nm laser focused through a 50x, 0.75 numerical aperture air 
objective (InVia microRaman, Renishaw), producing 2 μm diameter beam.  Peak heights were 
identified after subtracting background fluorescence using WiRE
TM
 V2.0 software (Renishaw).  
Spectra were taken on 5 lamellae spaced across the radii of the osteons, resulting in 15 
measurements per osteon (45 per animal). Spectra were acquired along the same radial lines 
characterized with nanoindentation and centered on lamellae when visible to match the 
nanoindentation locations as closely as possible.    
Three bone parameters were calculated:  mineral-to-matrix ratio, carbonate-to-phosphate 
ratio, and crystallinity [12,14,23,36–38].  Mineral-to-matrix ratio, a measure of the degree of 
mineralization of the tissue, was calculated as the ratio of the phosphate υ1 (~965 cm-1) to the 
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CH2 wag (~1450 cm
-1
) peaks [23].  The CH2 wag peak was used due to noise around the Amide I 
peak.  Carbonate-to-phosphate ratio, a measure of the level of carbonate substitution into the 
hydroxyapatite crystal lattice, was calculated as the ratio of the carbonate υ1 (~1070 cm-1) to the 
phosphate υ1 peak [37].  Crystallinity, a measure of crystal size and perfection, was estimated as 
the reciprocal of the full width at half maximum of the phosphate υ1 peak (FWHM) [36].  For 
this measure, a sharper phosphate υ1 peak (smaller FWHM) indicates greater mineral crystal size 
and perfection. 
 
2.2.4 Second Harmonic Generation Microscopy (SHG).  
SHG microscopy utilizes nonlinear scattering of photons from aligned collagen fibers 
within bone to create a map of aligned collagen content.  These measurements distinguish 
whether the collagen contained in the plane of measurement, in this case the transverse plane, is 
aligned within that plane.  The aligned collagen within the plane is proportional to the square 
root of SHG intensity [39–43].  A 2.5 W Ti:Sapphire (Mai Tai Deep See, Spectra Physics), with 
a pulse rate of 80 MHz at 780 nm was focused onto the samples with a 25x, 1.05 numerical 
aperture water objective (Olympus).   SHG photons were collected in epi mode and optically 
filtered to remove backscattered incident light. In-plane and out-of-plane focal volume 
dimensions (FWHM) were approximately 497 nm and 1500 nm, respectively.  SHG images of 
the three osteons analyzed with Raman spectroscopy and nanoindentation were taken as the 
Kalman average of 3 scans.  
The three radial lines per osteon characterized with nanoindentation and Raman 
spectroscopy were located on the SHG images.  For each pixel along the radial lines, the square 
root of the SHG intensity was averaged for a window 1 pixel wide and 4 pixels high (497 nm x 
1988 nm, Image J, National Institutes of Health).  For each lamella, maxima corresponding to 
lamellar aligned collagen and minima corresponding to interlamellar aligned collagen were 
recorded. Each osteon contained between 5 and 15 lamella, hence 15 to 45 maxima and minima 
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were recorded per osteon (~45 to 135 per animal).  The relative degree of aligned collagen for 
each lamellae was calculated as the peak height ratio of lamellar to interlamellar aligned collagen 
[31,34,44].  To isolate the contributors to changes in peak height ratio, lamellar and interlamellar 
values were determined individually and normalized by the mean aligned collagen content of the 
osteon to correct for intensity variations.   
 
2.2.5 Data Analysis 
All statistical testing for variations with animal and tissue age were performed on the raw, 
unaveraged data using linear models (JMP 7.0, SAS Institute, Inc.), with animal age (0.28-32.45 
years, n=12 animals), osteon (1–3, nested variable), radial line (1–3, nested variable), and 
distance from the center of the osteon (0-80 μm, representative of tissue age) as factors.  First, 
multi-factor ANOVAs tested whether relationships between parameters and animal age or tissue 
age depended on maturity (young, 0–5 years old, or mature, >5 years old) [27].  If maturity was 
not significant, a multi-factor ANOVA was performed on the combined data.  If maturity was 
significant, separate multifactor ANOVAs were run for young and mature data.  P-values less 
than 0.05 were considered significant. 
To correlate nanomechanical properties with compositional measures, the mean values of 
the outcome measures were calculated for each baboon.  Single-factor ANOVAs tested for the 
individual effect of each compositional measure on indentation modulus and hardness.  Then, 
multi-factor ANOVAs determined the combination of compositional parameters with greatest 
predictive power for indentation modulus and hardness.  A change of 0.05 in the coefficient of 
variation (R
2
) was considered an improved model fit. 
To visualize the tissue age data, results for a single animal were averaged by binning in 6 
μm increments across the 3 radii of the 3 sampled osteons.  Specifically, the mean distance from 
the center of the osteon and mean parameter values were calculated for each 6 μm bin of the 
indentation modulus and Raman data.   
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2.3   Results 
Sexual maturity (age≤5 years) significantly influenced indentation modulus but tissue age did 
not.  Indentation modulus increased steeply with animal age across young, sexually immature 
animals and increased gradually across sexually mature animals (Figure 2.2).  The magnitude of 
the increases were 1.85 GPa, or about 6.6%, per year across young animals (p<0.0001, ages 0.28 
to 2.81 years, n=6), and only 0.08 GPa, or 0.2% per year, across sexually mature animals 
(p=0.0058, ages 6.21 to 32.45 years, n=6) (Table 2.1).  Indentation modulus did not vary with 
tissue age across the osteon (Figure 2.2). 
  
Figure 2.2  Nanoindentation results versus animal and tissue age  (A) Indentation modulus and (C) 
hardness increased with animal age in the young animals and were constant after sexual maturity.  
Each point in (A) and (C) represents the mean ± SD of all measurements for a single animal (means ± 
SD used only for visual representation).  The dashed lines are from the ANOVA models for young and 
mature animals, which were performed on the raw, unaveraged data (45-135 measurements per 
animal).  (B) Indentation modulus and (D) hardness were constant with tissue age.  Increasing 
distance from the center of the osteon corresponds with increasing tissue age.  Open symbols with 
dashed lines represent young animals and solid symbols with solid lines represent mature animals.  
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Table 2.1  Significant variations of mechanical and compositional measures with animal and tissue age.  
Ranges reported for percent change across the osteon reflect variable osteon size.  NS = not significant, p 
≥ 0.05; young = 0 – 5 years; mature > 5 years.  
Hardness was significantly influenced by both sexual maturity and tissue age (Figure 
2.2).  Hardness increased steeply across young animals but showed no correlation with animal 
age in sexually mature animals (Figure 2.2).  In young animals, hardness increased 0.08 GPa, or 
about 6.8%, per year (p<0.0001, Table 2.1).  Hardness did not vary with tissue age across the 
osteon radii in young animals, but decreased with tissue age in mature animals, decreasing by 
0.3% per micron for a total decrease of 9-18% across the osteon radii (p=0.0008).   
Mineral-to-matrix ratio was affected by animal age but not tissue age.  Mineral-to-matrix 
ratio increased by 0.88, or about 12%, per year across young animals (p<0.0001), but was 
independent of age in mature animals (Table 2.1, Figure 2.3).  Mineral-to-matrix ratio was not 
correlated with tissue age across the osteon radii. 
Carbonate-to-phosphate ratio was affected by both animal age and tissue age.  Carbonate-
to-phosphate ratio increased by 0.01, or 6.7%, per year across young animals (p<0.0001) and 
was independent of animal age after sexual maturity (Table 2.1, Figure 2.3).  Carbonate-to-
phosphate ratio increased with tissue age across the osteon radii in both young and mature 
animals, increasing by 0.2% per micron (p<0.0001).   
Crystallinity varied with both animal age and tissue age.  Crystallinity increased by 
0.08% per year with animal age regardless of maturity (p<0.0001, Table 2.1, Figure 2.3), while 
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the increase in crystallinity with tissue age was greater in young than in mature animals.  In 
young animals, crystallinity increased by 0.1% per micron or 3-6% total across the osteon radii 
(p<0.0001).  In mature animals, the magnitude of the increase with tissue age was less than half 
that which occurred in young animals, 0.04% per micron or 1.2-2.4% total across the osteon radii 
(p<0.0001).   
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Figure 2.3  Raman spectroscopy results versus animal and tissue age.  (A) Mineral-to-matrix ratio and 
(C) carbonate substitution both increased in the young animals and were constant after sexual 
maturity, whereas (E) crystallinity increased with animal age independent of maturity. Each point in 
(A), (C), and (E) represents the mean ± SD of all measurements for a single animal (means ± SD used 
only for visual representation).  The dashed lines are from the ANOVA models, which were performed 
on the raw, unaveraged data (45 measurements per animal)  (B) Mineral to matrix ratio showed no 
change with tissue age, whereas (D) carbonate substitution increased with animal age, independent of 
maturity, and (F) crystallinity increased with tissue age faster in young than in mature animals.  
Increasing distance from the center of the osteon corresponds with increasing tissue age.  Open 
symbols with dashed lines represent young animals and solid symbols with solid lines represent mature 
animals. 
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Aligned collagen content varied with tissue and animal age (Figure 2.4).  The peak height 
ratio of lamellar to interlamellar aligned collagen increased by 4.6% per year with animal age in 
young animals, and by 0.45% per year in mature animals (p<0.0001) (Table 2.1).  This increase 
with animal age was due to both increased lamellar aligned collagen (+2.7% per year in young 
animals, and +0.22% per year in mature animals) and decreased interlamellar aligned collagen 
with animal age (-1.5% per year in young animals, -0.20% per year in mature animals).  With 
tissue age, collagen peak height ratio increased by 0.19% per micron, for a total increase of 6 to 
12% across the osteon radii, regardless of animal age (p<0.0001).  This increase was primarily 
due to increased lamellar aligned collagen (+0.30% per micron in all animals).  
 
When correlations between nanomechanical properties and composition were examined, 
indentation modulus and hardness were most influenced by mineral-to-matrix ratio (Figure 2.5).  
Mineral-to-matrix ratio alone explained 78% of the variation in indentation modulus (p<0.0001) 
and 70% of the variation in hardness (p<0.0004).  The only other significant relationship was 
with lamellar aligned collagen, which explained 30% of the variation in indentation modulus 
Figure 2.4 SHG results with animal and tissue age.  (A) Peak height ratio (lamellar/interlamellar 
aligned collagen) increased more with animal age in young than in mature animals.  Each point 
represents the mean ± SD of all measurements for a single animal (means ± SD used only for visual 
representation).  The dashed lines are from the ANOVA models for young and mature animals, which 
were performed on the raw, unaveraged data (45-135 measurements per animal)  (B) Peak height ratio 
increased with tissue age.  Increasing distance from the center of the osteon corresponds with 
increasing tissue age.  Open symbols with dashed lines represent young animals and solid symbols 
with solid lines represent mature animals. 
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R2=0.78
R2=0.70
R2=0.30
A
C
B
(p=0.0386), but did not significantly predict the variation in hardness (p=0.0939).  Combining 
lamellar aligned collagen with mineral-to-matrix ratio did not improve the predictive power for 
indentation modulus.   
 
2.4   Discussion 
We hypothesized that tissue mechanical properties would vary with changes in mineral and 
aligned collagen content as a function of both tissue and animal age.  Indeed, variations in the 
tissue mechanical properties correlated with mineral-to-matrix ratio and aligned collagen 
content.  Variations in mineral-to-matrix ratio were the most important predictor of variations in 
indentation modulus and hardness.  The addition of other parameters to mineral-to-matrix ratio 
Figure 2.5  Significant correlations between mean nanomechanical parameters and composition 
measures obtained from each animal.  Open symbols represent young animals and solid symbols 
represent mature animals.  Dashed lines and R
2
 values are from the ANOVA models.  (A) Indentation 
modulus versus mineral-to-matrix ratio.  (B)  Hardness versus mineral-to-matrix ratio.  (C)  Indentation 
modulus versus lamellar aligned collagen content.   
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did not add significant predictive value to the ANOVA models.  Mineral-to-matrix ratio 
effectively captured the variations explained by carbonate substitution and crystallinity 
(measures of the mineral), and lamellar aligned collagen (measure of the matrix).   
When the behavior of individual mechanical and compositional parameters was 
examined, indentation modulus, hardness, mineral-to-matrix ratio, carbonate substitution, and 
aligned collagen peak height ratio, followed biphasic relationships with animal age, increasing 
sharply in the first years of life, and then remaining constant with age after sexual maturity.  
Based on the linear fits, mineral-to-matrix ratio increased nearly twice as fast as indentation 
modulus and hardness in young, growing animals.  Of course, other microstructural factors such 
as mineral crystal size and orientation, collagen alignment, and noncollagenous matrix proteins 
may also contribute to the tissue mechanical properties [20,21,45].  Indeed, similar to stiffness, 
peak height ratio, a measure of aligned collagen content, followed a bi-phasic relationship with 
animal age.  Furthermore, after sexual maturity, stiffness increased at a gradual rate almost 
identical to that of the lamellar aligned collagen.  Although crystallinity showed a significant 
increase with animal age in mature animals, the percent changes were extremely small and may 
not be physiologically significant. 
 Carbonate substitution, crystallinity, and aligned collagen peak height ratio increased 
with tissue age, whereas mineral-to-matrix ratio and the mechanical parameters did not. 
Carbonate substitution increased at a gradual, constant rate throughout the lifespan of the 
baboon, suggesting that carbonate ions are substituted into the crystal lattice at a constant rate. 
Crystallization increased nearly an order of magnitude more rapidly in young than in mature 
animals, although again the percent changes were small.   
 In rodent models, increased mineralization, carbonate substitution, and crystallinity 
corresponded with increased stiffness and hardness, and similar to the current study, stiffness and 
hardness increased more gradually than did tissue mineralization [21,22,45,46].  Based on our 
data, these relationships hold true in a primate model that more closely parallels human bone 
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than other preclinical models.  Furthermore, variations in composition and nanomechanical 
properties were functions of tissue and animal age, a novel finding because prior studies have 
focused only on mature animals and showed variable relationships with ageing [14–17].  The 
mechanical properties also related to collagen content and organization, as previously reported in 
a small sample of human vertebrae [31,34].  This relationship held over the entire lifespan of the 
baboon, and reflected that both stiffness and aligned collagen content increased as functions of 
animal age.  Mineral-to-matrix ratio, carbonate substitution, indentation modulus, and hardness 
increased rapidly in the rat cortex to reach levels of mature tissue within the first four days after 
formation, but thereafter increased only slightly [20,21,45,46].  As baboon osteons selected for 
this study were not visibly remodeling, the tissue material properties would have already reached 
levels of the mature tissue and no steep increases in tissue material properties would be expected.  
Carbonate substitution and crystallinity did increase with tissue age across osteon radii, in 
agreement with data obtained through FTIR, a complementary spectroscopic technique [12]. 
As in any experiment, certain limitations may affect the interpretation of our results.  One 
consideration is that the exact age of the osteons could not be distinguished because 
fluorochrome labels were not administered to the animals.  However, by sampling three non-
remodeling osteons within the same anatomical region of the cortex, we hoped to reduce 
variability due to anatomical location.  The lack of steep gradients in tissue mineralization and 
stiffness near the Haversian canals confirmed that the selected osteons were not remodeling at 
the time of animal death.  Furthermore, although our composition data obtained by Raman 
spectroscopy is consistent with key points from that obtained by FTIR, one discrepancy is 
evident.  Namely, carbonate-to-phosphate ratio measured by FTIR decreased with animal age, 
whereas our Raman data showed increasing carbonate substitution during growth, followed by 
no change following sexual maturity [12,18].  This discrepancy may arise from fundamental 
differences between these two techniques; for example, Raman carbonate substitution is 
calculated from the peak height ratio rather than the peak area ratio used for FTIR.  Finally, 
 58 
 
although dehydration increases tissue modulus and hardness [47–49], all samples were treated 
similarly, and therefore our ability to detect variations in these properties with tissue and animal 
age was  presumably not compromised.   
 In summary, composition and mechanical function were closely related in baboon 
osteonal bone and depended on tissue and animal age.  When the entire lifespan of the animal 
was examined, tissue from the young, growing animals had lower stiffness and hardness, 
associated with lower mineralization, carbonate substitution, crystallinity, and aligned collagen 
content than tissue from sexually mature animals.  In future studies, fluorochrome labeling could 
help identify newly formed osteons to determine the full effect of tissue age within osteonal 
bone, while studies of male animals would allow identification of sex-based differences that are 
not age-dependent.  Based on the current results, we would expect the lamellae of newly formed 
osteons to have tissue properties similar to young, sexually immature animals.  These results 
provide a baseline for variations that occur in healthy bone tissue with the natural ageing process 
and may have clinical implications in osteoporosis, where increased bone loss is not coupled 
with new bone formation.  However, the relationship between fracture resistance and these age-
related changes in tissue composition and nanomechanical properties must be examined further.  
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CHAPTER 3 
VARIATIONS IN NANOMECHANICAL PROPERTIES AND TISSUE COMPOSITION 
WITHIN TRABECULAE FROM AN OVINE MODEL OF OSTEOPOROSIS AND 
TREATMENT
*
 
 
3.1 Introduction 
One in three women and one in five men over the age of fifty will experience an osteoporotic 
fracture in their lifetime [1–3].  The risk for additional fractures increases markedly after 
experiencing the first fracture [4].  Antiresorptive agents and selective estrogen receptor 
modulators (SERMs) reduce fracture risk from 30-50%, but increase BMD only slightly by 0-8% 
[5–10], suggesting that BMD alone is unable to fully capture skeletal alterations with treatment.  
BMD reflects the total amount of bone mineral (and the overall level of mineralization) but 
cannot capture effects at smaller length scales where failure initiates.  At these smaller length 
scales, skeletal fracture risk depends on tissue micro-architecture and properties of mineral and 
matrix constituents that can vary spatially within individual bone microstructures due to the 
remodeling process [11–18].  These spatial distributions are particularly important because small 
tissue property changes in critical locations for resisting trabecular failure can profoundly affect 
skeletal fracture resistance. Imbalances or alterations in the remodeling process with osteoporosis 
and treatment may alter levels and spatial distributions of mineral and matrix properties within 
bone microstructures and could play a crucial role in our understanding of fracture risk and our 
ability to develop and evaluate successful therapies.  
The mineralization gradient within trabeculae of healthy human bone is positive from 
surface to center and produces a positive gradient in tissue stiffness [15,19–22].  The manner in 
which individual trabeculae bear load is influenced by these tissue-level properties and their 
                                                 
*
 Burket JC, Brooks DJ, MacLeay JM, Baker SP, Boskey AL, van der Meulen MCH.  Variations in nanomechanical 
properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.  Submitted 
to Bone May 2012. 
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arrangement within trabeculae.  Osteoporosis reduces the overall heterogeneity of both tissue 
mineralization and mineral crystallinity [22–24], and bisphosphonate treatment further reduces 
heterogeneity in these properties [25–29].  However, the effects of osteoporosis and treatments 
on specific spatial distributions of compositional properties within trabeculae are not well-
documented and may depend on treatment type.  Mineral and matrix composition ultimately 
determine tissue mechanical function.  Thus, any heterogeneity in tissue compositional 
properties results in nanomechanical heterogeneity that alters profiles of stress and strain within 
trabeculae and possibly affects the bone composite’s ability to dissipate energy [14,17,18].  In 
healthy tissue, nanomechanical properties follow changes in mineralization and aligned collagen 
content [19,20,30].  Relationships between spatial compositional changes and the consequential 
nanomechanical alterations with osteoporosis and treatment have not yet been determined. 
The goal of the present study was to compare spatial compositional and nanomechanical 
alterations in trabeculae with a large-animal model of osteoporosis and treatment.  Two drugs 
were compared in this study.  The first was a selective estrogen receptor modulator (SERM) that 
reduces turnover by acting through natural estrogen receptor pathways in bone and mimicking 
the effects of estrogen.  The second treatment was from the widely-used bisphosphonate class of 
drugs that bind to bone matrix and directly inhibit osteoclastic activity upon resorption.  SERMs 
and bisphosphonates reduce bone turnover to varying degrees yet produce similar reductions in 
fracture risk [31,32].  In a previous study, bisphosphonates altered collagen cross-linking in 
healthy female beagle vertebrae whereas SERMs did not [33].  SERMs improved vertebral 
mechanical performance independently of BMD in these same animals, suggesting that other 
changes in tissue composition might play an important role in fracture resistance [34].     
Our hypotheses were that tissue stiffness and hardness would decrease in an ovine model 
of osteoporosis relative to healthy ewes due to alterations in tissue composition.  Conversely 
treatment with either raloxifene (SERM) or zoledronate (bisphosphonate) would restore tissue 
nanomechanical properties through further alterations in tissue composition.  Greatest effects 
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were expected near surfaces of trabeculae in regions of active remodeling and bone formation.  
Additionally, nanoscale rather than bulk tissue measures were predicted to better capture these 
changes with treatment because of their better spatial resolution.  Tissue property effects with 
zoledronate were expected to be more pronounced than effects with raloxifene because 
bisphosphonates reduce turnover to a greater degree than SERMs [32,34].  However, raloxifene 
treatment was expected to better restore cancellous tissue properties to those present in healthy, 
ovary intact female sheep, since SERMs act through natural estrogen receptor pathways [35].   
 
3.2 Materials and Methods 
The present study utilized a dietary-induced ovine model of osteoporosis and treatment to 
examine alterations in bone tissue compositional and nanomechanical properties, and changes in 
the spatial arrangements of these properties within trabeculae.  The microstructure of sheep bone 
is similar to that of humans [36–40].  In a previous study, dietary-induced metabolic acidosis 
(MA) in sheep increased bone turnover and reduced bone mineral and whole bone strength 
similar to postmenopausal osteoporosis in humans [36,39,41].  In contrast, the ovine ovariectomy 
(OVX) model decreased bone turnover and caused osteomalacia [41], making MA the 
appropriate model choice for post-menopausal, high-turnover osteoporosis.  Two different 
antiresorptive treatments were examined in this study:  the SERM, raloxifene (RAL), and the 
bisphosphonate, zoledronate (ZOL).   
 
3.2.1 Samples and Specimen Preparation 
Femora were obtained from 25 mature adult ewes from 2 experiments (approved by the Colorado 
State University Institutional Animal Care and Use Committee).  The first experiment had two  
experimental groups.  Both groups were fed a diet to induce metabolic acidosis for six months 
followed by another six months of MA with either vehicle (MA1, n = 5) or raloxifene (RAL, 
0.80 mg/kg daily, n = 4) administered daily through abomasal cannulae [39,41].  Both treatment 
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groups started with n = 6 sheep; however, two RAL sheep were euthanized early due to cannula 
pull-out and one MA sheep was euthanized due to injuries unrelated to the experiment.  A group 
of healthy animals fed a normal diet (CONT, n = 5) were housed in the same facility and 
euthanized in the same season as Experiment 1.  The second experiment had two treatment 
groups.  Both groups received eight months of MA rather than 6 months due to a delay in 
receiving the medication for the study.  Subsequently, the groups were maintained on the MA 
diet for an additional 6 months with an intravenous administration of either vehicle (MA2, n = 6) 
or zoledronate (ZOL, 5 mg/sheep, n = 6) at the beginning of the treatment period.  Originally, the 
bisphosphonate and SERM treatments were planned as a single experiment; however, due to 
difficulty administering alendronate in the first study, the bisphosphonate study was repeated 
separately using zoledronate with the MA2 group for comparison.  After euthanasia, femora 
were stored at -20º C prior to specimen preparation. 
 
3.2.2 Bulk Cancellous Tissue Characterization 
Cylindrical cores were taken from the medial-caudal quadrants of the distal femur for 
characterization by micro-computed tomography (microCT) and compression tests.  Cores were 
excised with a diamond core drill (5 mm ID, Starlight Industries, Rosemont, PA) under constant 
irrigation with physiological saline, wrapped in saline-soaked gauze, and stored at -20˚C prior to 
scanning. 
 
3.2.2.1 Micro-Computed Tomography (MicroCT) 
Tissue architecture within the cancellous cores was quantified by microCT (55 kVp, 145 mA, 
600 ms integration time, µCT 35, Scanco Medical, Bruttisellen, Switzerland).  The axial central 
third of each core was scanned at 15 µm isotropic resolution. A calibrated HA standard was used 
to convert the linear attenuation for each voxel to g HA/cm
3
.  A 0.5 mm aluminum filter reduced 
the effects of beam hardening. A global threshold was chosen for all specimens.  Outcomes 
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included bone volume fraction (BV/TV), tissue mineral density (tBMD, mg/cm
3
), and trabecular 
thickness and separation (Tb.Th and Tb.Sp, mm). 
 
3.2.2.2 Compression Testing and Ashing 
Bulk cancellous mechanical properties were assessed by compression testing of the bone cores. 
Prior to testing, press-fit brass end-caps were bonded to the ends of each core to minimize end 
artifacts [42].  The average gage length and diameter of the exposed core between endcaps was 
measured and used for subsequent stress and strain calculations.  The load function consisted of 
5 preconditioning cycles of 0 to 0.1% compressive strain before monotonically loading to 3% 
compressive strain at a rate of 0.5% strain/sec using a servohydraulic test system (Mini-Bionix 
858, MTS Systems Corporation, Eden Prairie, MN).  Displacement was measured with an 
extensometer attached across the endcaps (Model 634.11F-24, MTS Systems Corporation).  The 
apparent compressive modulus, yield strength, and ultimate compressive strength were 
determined for each core.  The apparent compressive modulus was defined as the slope of the 
least-squares fit of the stress-strain data over 0.02-0.2% strain.  The yield strength was 
determined using the 0.2% offset method, and the ultimate compressive strength was the 
maximum stress achieved [43].  Following compressive testing the bone cores were  dried and 
heated to 600 ºC for 18 hours, and ash fraction was calculated as ash weight/dry weight [44]. 
 
3.2.3 Nanoscale Cancellous Tissue Characterization 
Transverse cancellous sections were taken above the growth plate of the medial-cranial 
quadrants of the distal femora for nanoscale characterization of compositional and 
nanomechanical properties.  Sections were fixed, dehydrated, and embedded in 
polymethlymethacrylate [45].  A thin section (3 μm) was taken from the surface of each 
embedded bone block and mounted on a barium fluoride infrared spectroscopy window (Spectral 
Systems, Hopewell Jct., NY).  The adjacent surface of the remaining block was polished 
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anhydrously to a RMS surface roughness of less than 15 µm on a 5 µm
2
 AFM Scan (Dimension 
3100, Veeco, Plainview, NY) [30,46,47].   
Three trabeculae in each block and adjacent thin section were selected for 
characterization.  In the three trabeculae from the blocks, tissue nanomechanical properties and 
composition were probed at identical locations with nanoindentation, Raman spectroscopy, and 
second harmonic generation microscopy (SHG).  In the three trabeculae from the thin sections, 
tissue compositional parameters were assessed with Fourier transform infrared spectroscopy 
(FTIR).  All nanoscale tissue property measurements were recorded in transverse lines across the 
trabeculae avoiding locations of remodeling at the time of euthanasia, which were visibly evident 
as regions of eroded trabeculae with scalloped surfaces.   
The criterion for selecting trabeculae in this study was critical for examining regional 
results within these structures.  The mean width of selected trabeculae was no less than 70% of 
the mean Tb.Th computed individually from the micro-CT measurements.  This criterion ensured 
that trabeculae selected for analysis were sectioned close to their midsection (bisected in the 
longitudinal plane of the trabeculae).  Hence, properties could be examined in superficial regions 
near the edges of trabeculae and in deeper tissue near the center of the trabeculae.  Additionally, 
the SHG instrument for this study could image up to 60 µm below the surface of the sample in 
confocal mode to confirm that the exposed plane for measurement was not superficial and 
contained sufficient tissue for nanomechanical analysis.   
 
3.2.3.1 Nanoindentation 
Tissue nanomechanical properties were assessed via nanoindentation at centers of lamellae in a 
transverse line across three trabeculae with a Berkovich diamond indenter (Hysitron, Inc., 
Minneapolis, MN) [48,49].  For accurate placement, surface topography scans (20 μm2) were 
made with the scanning nanoindenter (TriboIndenter, Hysitron, Inc.) prior to each indentation 
[30,46–49].  The load function included a 10 second hold at 700 µN peak load with 
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loading/unloading rates of 50 µN/s [48].  The resulting indentation depth was approximately 150 
nm. 
Each trabecula contained a mean of 13 (± 3) lamellae, resulting in roughly 40 
measurements per animal. Indentation modulus (Ei), a measure of tissue stiffness (i.e. elastic 
properties), and hardness, a measure of inelastic properties, were calculated from the unloading 
portion of the load-displacement curve and the mean pressure at maximum load, respectively 
[50].   
 
3.2.3.2 Raman Spectroscopy 
 Tissue composition was characterized with Raman spectroscopy, as described previously [48], 
at the same lamellar locations characterized with nanoindentation (InVia microRaman, 
Renishaw, Gloucestershire, United Kingdom).  The spot size was 2 μm2.  For each measurement, 
Raman peak heights were identified from smoothed spectra after cubic polynomial background 
subtraction (Matlab, The Math Works, Inc., Natik, MA).  Three bone parameters were 
calculated:  mineral-to-matrix ratio (Raman mineral:matrix), B-type carbonate substitution, and 
crystallinity (Raman crystallinity) [48,51–56].  Mineral-to-matrix ratio, a measure of the degree 
of mineralization of the tissue, was calculated as the peak height ratio of the phosphate υ1 (~965 
cm
-1
) to the CH2 wag (~1450 cm
-1
) peaks [48,52].  B-type carbonate substitution, a measure of 
the level of carbonate substitution for phosphate in the hydroxyapatite (HA) crystal lattice, was 
calculated as the peak height ratio of the carbonate υ1 (~1070 cm-1) to the phosphate υ1 peak 
[48,55].  Raman crystallinity, a measure of crystal size and perfection, was estimated as the 
reciprocal of the full width at half maximum (FWHM) of the phosphate υ1 peak [48,54,56].  For 
this measure, a sharper phosphate υ1 peak decreases FWHM and indicates greater mineral 
crystal size and perfection.   
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3.2.3.3 Second Harmonic Generation Microscopy (SHG) 
Aligned collagen content within a longitudinal plane of the trabeculae was assessed via SHG 
microscopy as described previously [48] in the same trabecular regions studied with 
nanoindentation and Raman spectroscopy (Mai Tai Deep See, Spectra Physics, Santa Clara, CA; 
BX61W1, Olympus, Center Valley, PA).  The pixel size was 0.318 µm
2
.  Fiducial markers such 
as osteocyte lacunae were compared with light microscopy images to co-locate SHG 
measurements with nanoindentation and Raman measurements. 
The concentration of aligned collagen molecules (aligned collagen content) is equal to the 
square root of SHG intensity [57–61].  The aligned collagen content was calculated for a 
transverse line across each trabecula resulting in a profile of aligned collagen content with 
distance (Matlab, The Math Works, Inc.).  The line was 6 pixels wide, corresponding to the 
Raman spot size of 2 µm.  From this profile, maxima corresponding to lamellar aligned collagen 
and minima corresponding to interlamellar aligned collagen were recorded [30].  
 
3.2.3.4 Fourier Transform Infrared Spectroscopy (FTIR) 
Tissue composition was characterized in three trabeculae with FTIR spectroscopy, a 
complementary vibrational spectroscopy to Raman (Spectrum Spotlight 3000, Perkin Elmer 
Instruments, Waltham, MA) [49,62,63].  Due to the thin-section requirements for FTIR, these 
trabeculae were not the same as those characterized with the other techniques; however, FTIR 
sections were taken adjacent to the polished bone surfaces so anatomically similar areas were 
characterized.  The pixel size was 6.25 μm2.  Four outcome measures were calculated (ISYS 4.0, 
Spectral Dimensions, Olney, MD) [62,64]:  Mineral-to-matrix ratio (FTIR mineral:matrix), a 
measure of tissue mineralization, was calculated as the integrated area of the phosphate peak 
from 916 – 1180 cm-1 over the area of the amide I mode from 1592 – 1712 cm-1[65,66]; total 
carbonate substitution, a measure of all carbonate substituted in to the HA crystal lattice 
(substitution for phosphate and hydroxyl, and labile substitution) was calculated as the integrated 
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area of the carbonate ν2 peak from 840 – 892 cm-1 to the area of the phosphate peak [67];   FTIR 
crystallinity, a measure of stoichiometric to non-stoichiometric mineral content that correlates 
with c-axis line broadening as assessed by x-ray diffraction, was calculated as the ratio of the 
peak height sub-band at 1030 over the sub-band at 1020 cm
-1
 within the phosphate contour 
[68,69]; and finally, collagen cross-linking network maturity (XLR), a measure of  the ratio of 
mature pyridinoline cross-links (PYR) to immature, reducible collagen cross-links (deH-
DHLNL, deH-HLNL, and deH-HHMD) was calculated as the ratio of the peak height sub-band 
at 1660 to the sub-band at 1690 cm
-1
 [70].  From the FTIR images, the mean value of each 
parameter versus distance from the edge of the trabecula was calculated (Matlab). 
 
3.2.4 Statistical Analysis 
Statistical analyses were performed separately for Experiment 1 and 2, i.e. RAL was compared 
only with MA1 and CONT, while ZOL was compared only with MA2 (JMP Pro 9.0, Cary, NC).  
CONT animals were included with Experiment 1 for statistical analyses because they were 
housed in the same facility and euthanized shortly after the first experiment in the same season 
(summer).  Experiment 1 and 2 analyses were performed separately due to the experiments being 
conducted separately and because animals were euthanized in the summer for Experiment 1 and 
winter for Experiment 2.  In the sheep, BMD is constant during summer months; however 
seasonal variations can be present between summer and winter [71].   
The effects of treatment on bulk tissue outcome measures (from microCT, compression 
testing, and ashing) were assessed with single-factor ANOVAs with Tukey post-hoc tests.  The 
significance level was p ≤ 0.05.  Results stated are significant unless noted otherwise.  Figures 
display mean values with error bars representing 95% confidence intervals. 
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3.2.4.1 Nanoscale Effects of Treatment and Region 
To determine effects of treatment and distance from the edge of the trabeculae on 
nanoscale mechanical and compositional properties from nanoindentation, Raman, SHG, and 
FTIR, measurements were classified by region within the trabeculae:  Superficial (Sup, < 20 μm 
from the trabecular edge), Intermediate (Int, 20 – 40 μm from the trabecular edge), and Central 
(Ctr, > 40 μm from the trabecular edge) [19,20,72,73].  Multi-factor, nested ANOVAs with 
Tukey post-hoc tests determined effects of treatment (CONT, MA, and RAL; MA2 and ZOL), 
region (Superficial, Intermediate, and Central), treatment*region, sheep (nested), and trabeculae 
(nested). 
 
3.2.4.2 Correlations Between Compositional and Nanomechanical Parameters 
The contribution of compositional properties (Raman and SHG) to alterations in tissue 
nanomechanical properties was determined by regression analysis. The mean Superficial, 
Intermediate, and Central values for the compositional and mechanical parameters were 
calculated for each trabecula.  Correlating these averaged values rather than each individual 
measurement location reduced variability from inherent heterogeneity of the bone tissue or slight 
misalignment between measurement locations. 
Correlations were performed separately for Experiment 1 and Experiment 2.  First, linear 
ANOVA models were performed for Ei and H vs. Raman mineral-to-matrix ratio, B-type 
carbonate substitution, Raman crystallinity, and lamellar aligned collagen.  Subsequently, non-
significant terms were removed from the model stepwise in order of decreasing p-value until 
only significant effects remained.  Next, treatment and full interactions between compositional 
parameters and treatment were added to the ANOVA models.  Non-significant terms were again 
removed in a stepwise fashion until only significant effects remained.  For significant 
improvement in explanatory power, a minimum 5% increase in the R
2
 value was considered 
practically meaningful. 
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3.3 Results 
 
3.3.1 MA and Treatment 
MA and treatment effects were more apparent at the nanoscale than at the bulk tissue level.  MA 
did not differ significantly from controls for any of the bulk compression outcome measures 
(Figure 3.1), due at least in part to substantial variability between animals and small sample 
sizes.  Bulk microCT demonstrated reduced tBMD with MA, with MA1 ewes having 3% lower 
tBMD than control animals (Figure 3.2).  At the nanoscale, MA ewes had lower indentation 
modulus (-15%) and hardness (-13%) throughout trabeculae relative to control animals (Figure 
3.3).  Compositional measures at indentation locations showed reduced B-type carbonate 
substitution in Superficial (-11%) and Intermediate regions (-11%) in MA relative to control 
ewes (Figure 3.4).  Complementary FTIR compositional measurements showed less total 
carbonate substitution throughout the trabeculae in MA sheep relative to controls, with the 
magnitude of the difference depending on region (Superficial -14%, Intermediate -8.3%, Central 
-12% vs. CONT; Figure 3.5).  In addition, Superficial regions of MA trabeculae had lower FTIR 
mineral-to-matrix ratio (-8.1%), lower collagen cross-linking network maturity (-9.2%), and 
greater FTIR crystallinity (+3.4%) than that of controls (Figure 3.5).    
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Figure 3.1  Bulk tissue results from compression testing of cancellous cores.  (A) Young’s modulus, 
(B) ultimate stress, (C), yield stress, and (D) yield strain.  Cores were ashed after compression testing 
but did not show any differences between treatment groups.  * p < 0.05  All figures show mean ± 95% 
confidence interval.   
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Figure 3.2  Bulk tissue results from microCT of cancellous cores.  (A) BV/TV, (B) tBMD, (C) Tb.Th., 
and (D) Tb.Sp.  * p < 0.05  ** p < 0.10 
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Figure 3.3  Nanomechanical results.  (A) Indentation modulus and (B) hardness by trabecular 
region.  Effects of DIMA and RAL are evident throughout trabeculae, whereas ZOL alters only 
Superficial regions. Significant differences are indicated by < and > ; equivalence indicated by ≈. 
 
Figure 3.4  Raman compositional results.  (A) Raman mineral-to-matrix ratio, (B) Raman 
crystallinity, and (C) B-type carbonate substitution by trabecular region.  Raman measurements were 
made at nanoindentation locations.  Significant differences are indicated by < and > ; equivalence 
indicated by ≈. 
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Figure 3.5  FTIR compositional results.  (A) FTIR mineral-to-matrix ratio, (B) FTIR crystallinity, (C) 
total carbonate substitution, and (D) collagen cross-linking network maturity by trabecular region.  
FTIR measurements were made in thin sections taken adjacent to trabeculae characterized with 
nanoindentation, Raman, and SHG.  Significant differences are indicated by < and > ; equivalence 
indicated by ≈. 
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Like MA, RAL treatment effects were greater at the nanoscale than at the bulk tissue 
level.  The decreased bulk tBMD with MA was restored with RAL, with RAL-treated animals 
achieving tBMD levels equivalent to controls (Figure 3.2).  At the nanoscale, indentation 
modulus (+9.6%) and hardness (+9.9%) increased with RAL compared to MA animals 
throughout trabeculae, but these properties were not fully restored to control levels (Ei -6.5%, H -
4.6% vs. CONT; Figure 3.3).  Measurements of tissue composition at indentation locations 
showed that RAL did not alter the reduction in B-type carbonate substitution that occurred with 
MA (Figure 3.4); furthermore, total carbonate substitution was reduced even further with RAL 
over MA, with the magnitude of the decrease greater at Superficial regions than in deeper tissue 
(Superficial -36%, Intermediate -30%, Central -27% vs. CONT, Figure 3.5).  RAL restored 
collagen cross-linking network maturity (XLR) to levels in controls, and increased FTIR 
mineral-to-matrix ratio (Superficial +9.2%, Intermediate +12%, Central +19% vs. CONT) and 
FTIR crystallinity (Superficial +6.6%, Intermediate +6.5%, Central +4.6% vs. CONT) 
throughout trabeculae, with the magnitudes of the increases varying by region.  FTIR mineral-to-
matrix ratio and crystallinity reached levels greater than those in control animals (Figure 3.5).  
 
Figure 3.6  SHG results.  (A) Lamellar aligned collagen and (B) interlamellar aligned collagen by 
trabecular region.  SHG measurements were taken at locations characterized with nanoindentation 
and Raman.  Significant differences are indicated by < and > ; equivalence indicated by ≈. 
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Treatment effects with ZOL differed from those with RAL at both the bulk tissue level 
and the nanoscale.  In bulk tissue ZOL decreased yield strain (-23%) and trended towards 
increased trabecular thickness (+ 30 µm or 19%, p < 0.06) relative to MA animals (Figures 3.1 
and 3.2).  Consequently, Superficial regions of ZOL trabeculae consisted primarily of newly 
formed tissue.  Unlike RAL, ZOL did not affect tBMD.  Nanomechanical properties were altered 
exclusively in Superficial regions with ZOL, with these regions having greater indentation 
modulus (+12%) and hardness (+16%) than in MA animals (Figure 3.3).  Nanoscale 
compositional measurements at indentation locations showed that Raman mineral-to-matrix ratio 
was also greater in Superficial regions with ZOL (+10%) than with MA, whereas B-type 
carbonate substitution increased (+4.7%) and aligned collagen content (lamellar -13%, 
interlamellar -12%) decreased throughout trabeculae with ZOL (Figures 3.4 and 3.6).  From the 
adjacent thin sections, FTIR mineral-to-matrix ratio, FTIR crystallinity, total carbonate 
substitution, and collagen cross-linking network maturity were altered with ZOL relative to MA 
(Figure 3.5), but percent changes were less than 3% and likely not physiologically meaningful 
although statistically significant. 
 
3.3.2 Correlations between Compositional and Nanomechanical Parameters 
For Experiment 1 (CONT, MA1, and RAL), indentation modulus and hardness correlated 
with B-type carbonate substitution, Raman crystallinity, and lamellar aligned collagen (Table 
3.1, Figure 3.7).  These three compositional measures explained 28% and 25% of the variation in 
indentation modulus and hardness, respectively.  The predictive power for indentation modulus 
and hardness increased to ~35% when treatment and its effects on compositional relationships 
were included.  When the contributions of each compositional parameter were examined 
individually, B-type carbonate substitution and Raman crystallinity were the strongest predictors 
of nanomechanical function and correlated positively with both indentation modulus and 
hardness.  B-type carbonate substitution and Raman crystallinity, respectively, explained 20% 
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and 10% of the variation in indentation modulus independent of treatment.  In contrast, 
relationships between hardness and these two parameters varied between treatment groups.  B-
type carbonate substitution was only a significant predictor of hardness in MA and RAL ewes, 
both of which had lower levels of carbonate substitution than control animals.  Raman 
crystallinity significantly predicted hardness only with RAL and accounted for 46% of the 
variation in hardness in these animals, the greatest explanatory effect measured.  
 
  
Table 3.1  Coefficients of variation (R
2
) for nanomechanical properties modeled as linear functions of 
Raman and SHG compositional parameters for each experiment.  “Composition Only” indicates the 
explanatory power of the linear models with four compositional parameters:  Raman mineral:matrix, 
B-type carbonate substitution, Raman crystallinity, and lamellar aligned collagen.  “Composition + 
treatment” indicates the explanatory power of the models with the four compositional parameters, 
treatment, and the effects of treatment on the nanomechanical relationships with composition.  
+
 
Indicates compositional parameters whose effects varied with treatment.  An increase in R
2
 > 0.05 is 
considered a meaningful improvement. 
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The ANOVA models for Experiment 2 explained less of the variability in 
nanomechanical parameters than those for Experiment 1.  Indentation modulus and hardness 
correlated positively with Raman mineral-to-matrix ratio and crystallinity.  Hardness also 
correlated with lamellar aligned collagen.  Composition accounted for 15% of the variability in 
indentation modulus and was not affected by treatment.  Compositional parameters alone 
explained only 7% of the variability in hardness.  Allowing the relationship between hardness 
and lamellar aligned collagen to vary with treatment increased the explanatory power to 12%.    
When the contributions of each compositional parameter to the ANOVA models were examined 
individually, Raman mineral-to-matrix ratio provided the most explanatory power and predicted 
11% of the variation in indentation modulus independent of treatment.  Hardness also correlated 
Figure 3.7  Measured values of indentation modulus and hardness from Experiment 1 (A and C) and 
Experiment 2 (B and D) plotted versus the predicted values from the ANOVA models including 
treatment and significant compositional parameters (Table 1).  Relationships between 
nanomechanical and compositional parameters were allowed to vary between treatment groups.   
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with Raman mineral-to-matrix ratio, which explained only 2.4% of the variation and provided 
limited predictive utility. 
 
3.4 Discussion 
As hypothesized, raloxifene and zoledronate reversed changes in cancellous bone tissue 
properties in a large-animal model of human osteoporosis, and these improvements correlated 
with changes in composition.   Bulk tissue properties such as tBMD were not sensitive enough to 
capture treatment effects, which became more apparent at the nanoscale and varied spatially 
within cancellous microstructures.  Not surprisingly, nanoscale effects differed between the two 
treatments.  Raloxifene reversed MA-induced losses in stiffness and hardness throughout the 
trabeculae but did not fully restore levels to those present in healthy ewes.  Alterations in tissue 
mineralization, lamellar aligned collagen content, and Raman crystallinity accounted for one 
quarter to one third of the variation in nanomechanical parameters with MA and raloxifene.  In 
comparison, zoledronate improved tissue stiffness and hardness over MA exclusively at the 
surfaces of trabeculae.  Nanomechanical improvements with MA and zoledronate correlated with 
tissue mineralization, crystal size and perfection, and B-type carbonate substitution.  In both 
experiments, the relationships between indentation modulus and compositional parameters were 
independent of treatment while relationships between hardness and compositional parameters 
differed between treatment groups.   
The most pronounced treatment effects were expected at surfaces of trabeculae, regions 
where active remodeling and bone formation take place.  Surface tissue is younger and less 
mineralized due to the remodeling process in cancellous bone and consequently has the greatest 
potential for gains in mineralization [21,74–76].  Tissue nanomechanical properties positively 
correlate with mineralization [48,74–77].  Additionally, bisphosphonates such as zoledronate 
target to bone matrix on trabecular surfaces where they directly inhibit osteoclast activity when 
resorbed by these cells [78–83].  Indeed, our results confirm zoledronate treatment effects were 
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primarily on surfaces of trabeculae and locally increased mineral-to-matrix ratio followed by 
gains in tissue stiffness and hardness.  These results confirm findings from 12 months of 
zoledronate treatment in an ovine OVX model [20].  We further show that these surface regions 
consist primarily of newly formed tissue, as indicated by the trend towards increased trabecular 
thickness with zoledronate. 
In contrast, treatment effects with the SERM, raloxifene, were distributed throughout the 
thickness of the trabeculae and not limited to surfaces.  Raloxifene acts as an agonist in bone and 
reduces turnover by binding to estrogen receptors and acting through estrogen response elements 
and coregulator proteins (IL-6, IL-7, TGF-β, etc.) [35,84].  Turnover is reduced less with 
raloxifene than with zoledronate and other bisphosphonates both in women with osteoporosis 
and animals with replete estrogen levels [10,32].  Bulk tissue measures in the current study 
showed no increase in trabecular thickness with RAL.  Thus, gains in tissue stiffness and 
hardness throughout trabeculae were achieved by increased mineralization of existing trabecular 
tissue, as evidenced by the increase in FTIR mineral-to-matrix ratio throughout trabeculae.  
Our results provide interesting insights into the mechanisms by which anti-resorptive 
treatments achieve remarkable reductions in fracture risk despite only modest increases in BMD.  
If a single trabecula for each treatment were modeled as a perfect cylinder with average 
trabecular width and regional tissue stiffness as measured in these experiments, raloxifene and 
zoledronate would increase trabecular bending stiffness over their corresponding MA groups by 
60% and 110%, respectively. With raloxifene, the trabecular bending stiffness would still be 
15% less than that of healthy trabeculae, but with zoledronate, trabecular bending stiffness would 
be 28% greater than that from a healthy sheep from Experiment 1.  The greater increase in 
trabecular bending stiffness with zoledronate is attributable to both the trend towards greater 
trabecular thickness and the localized increase in tissue stiffness near surfaces of trabeculae.  
Bending and buckling are two dominant failure modes for individual trabeculae within 
cancellous bone, and both are most influenced by the quantity and properties of tissue located 
 85 
 
farthest away from the center (or neutral axis) of the trabeculae.  By increasing tissue stiffness 
near the surface, zoledronate targets the exact region most critical for resisting bending and 
buckling failure.  Though these effects within trabeculae did not translate to changes in the bulk 
tissue mechanical properties measured in this experiment, localized improvements with 
zoledronate treatment could account for some of the discrepancy between the small change in 
BMD and the much greater decrease in fracture risk observed clinically with bisphosphonate 
treatment.  Continued treatment duration beyond the six months studied here could produce more 
pronounced effects and eventually translate to changes measurable in bulk tissue. 
The nature of mineral-to-matrix alterations differed between raloxifene and zoledronate, 
as evidenced by differences in Raman and FTIR compositional parameters.  Zoledronate affected 
primarily the peak vibrations of phosphate υ1 and CH2 wag [48,52].  In contrast, raloxifene 
altered the entire phosphate υ1 and Amide I vibrational modes [65,66] but had little effect on 
peak phosphate υ1 and CH2 wag vibrations.  Zoledronate effects were most evident from Raman 
measurements made at peaks of lamellae, while raloxifene effects were most evident from SHG 
measurements that reflect both lamellar and interlamellar material due to the lower spatial 
resolution.   
Previously, decreased carbonate substitution was associated with increased atomic order 
in synthetic apatites [85].  All types of carbonate substitution decreased with MA and raloxifene 
and indeed this corresponded with increased stoichoimetric/non-stoichiometric crystallinity ratio 
measured by FTIR.  Unlike raloxifene, zoledronate increased B-type carbonate substitution over 
MA but decreased the combination of A-type and labile carbonate substitution.  As a result, the 
difference in total carbonate substitution with zoledronate was small and likely not 
physiologically significant. 
The treatment-dependent relationships between hardness and compositional parameters 
suggest that the nature of mineral and matrix alterations differ between treatments and depend on 
additional factors not captured by the four compositional parameters correlated in this study.  
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Furthermore, compositional correlations provided limited explanatory power for the 
nanomechanical parameters, particularly in Experiment 2, and also point towards contributions 
from aspects of mineral and matrix composition not measured here.   Factors such as other non-
enzymatic collagen cross-links, mineral crystal orientation, and non-collagenous proteins could 
also play a role in mechanical function.  In addition, the nanoscale data from Experiment 2 fell in 
a narrow range, such that treatment and regional differences were on a scale not much larger than 
the biological variability. 
The present study had several methodological limitations that could affect the 
interpretation of the results.  First, the sample size of the large animal model was underpowered 
for the bulk tissue measures.  In addition, large variations in bulk tissue measures between 
animals made differences with treatment difficult to detect.  A power analysis based on our 
results showed that a three-fold increase in sample size was needed to detect significant changes 
in BV/TV and a two-fold increase for Tb.Th.  Nanomechanical measurements benefitted from 
repeated measures to increase statistical power.  Nonconcurrent performance of the two 
experiments prevented direct statistical comparison between all treatment groups.  Ideally, 
controls would have been included as part of the experimental design; however, little effect was 
expected due to different treatment and euthanasia dates because control animals were housed in 
the same facility and euthanized in the same season.  Additionally, performing statistical models 
without control animals did not significantly alter the results or predictive capability.  The delay 
in administering zoledronate in Experiment 2 prolonged the DIMA period by two months and 
caused animals in Experiment 2 to be euthanized in a different season than in Experiment 1.  
Both factors could produce slight differences between the two MA groups and the severity of 
bone loss at the start of treatment.  The MA model presents another limitation because ewes were 
estrogen-replete, unlike post-menopausal osteoporotic patients.  Notably, the presence of 
estrogen in the MA animals may have blunted the effects of raloxifene, since SERMs and 
estrogen act through the same estrogen receptor pathways [35,84].  Finally, FTIR measurements 
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were not colocalized with other nanoscale measurements due to the thin-section requirement, 
limiting comparisons to trends rather than direct correlations among parameters. 
In conclusion, both raloxifene and zoledronate improved cancellous tissue 
nanomechanical properties in the distal femur of a large-animal model for human high-turnover 
osteoporosis, and these improvements were attributable to changes in tissue composition.  A 
companion study compares the FTIR changes in the distal femur to changes in other bones from 
the same animals [86].  In the present study, alterations were less evident at the bulk tissue level 
than at the nanoscale—the length scale at which failure initiates.  Zoledronate improvements 
were localized to new tissue at surfaces of trabeculae, where the drug binds to bone matrix and 
directly reduces osteoclastic activity.  In contrast, raloxifene acts through estrogen receptor 
pathways and improved tissue properties throughout the trabeculae.  The nanoscale spatial 
alterations in composition and consequently nanomechanical properties resulted in 
improvements in estimated trabecular bending stiffness.  As the fracture of cancellous bone 
ultimately arises due to the failure of individual trabecular elements, these findings may provide 
some explanation for the reductions in fracture risk with SERM and bisphosphonate treatment 
despite only modest gains in BMD.   
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CHAPTER 4 
COMPOSITIONAL AND MECHANICAL EFFECTS OF BISPHOSPHONATE AND SERM 
TREATMENTS IN CORTICAL TISSUE FROM AN OVINE MODEL FOR HUMAN 
OSTEOPOROSIS 
 
4.1 Introduction 
The increased propensity for fracture with osteoporosis results from deterioration of both 
cancellous and cortical bone [1–10].   Fragility fractures occur at primarily cancellous sites such 
as the hip, wrist, and vertebrae [11,12], and consequently most studies focus on treatment effects 
in cancellous tissue while neglecting effects in cortical bone.  The cortical shell becomes 
increasingly important for load bearing and fracture resistance with the preferential loss of 
cancellous bone with osteoporosis [2–5,13].  Additionally, The effects of treatments are often 
markedly different in cortical and cancellous tissue [14–17].  Therefore, cortical tissue is critical 
to evaluate the effectiveness and success of potential osteoporosis therapies. 
Failure of cortical bone initiates with damage and microcracking at the tissue-level and is 
influenced by spatial distributions of properties within osteons and interstitial tissue [18–24].  
Tissue composition and nanomechanical properties vary spatially within cortical bone due to the 
remodeling process and random biological variability, with tissue stiffness and hardness 
generally following trends in mineralization and aligned collagen content [25–30].  Thus, the 
newer, less-mineralized osteons in healthy human cortical bone have lower stiffness and 
hardness than older, more mineralized interstitial tissue [28,31–33].  Micro-CT based models of 
human cortical bone suggest nanoscale mechanical heterogeneity within cortical bone may 
promote energy dissipation [18,19].  Experimentally, nanomechanical differences between 
osteons and interstitial tissue influence fracture toughness [20–24]. 
Few studies have examined the effects of osteoporosis and antiresorptive treatments on 
nanoscale distributions of tissue composition and nanomechanical properties within cortical bone 
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[15,34].  Furthermore, the effects of nanoscale compositional and nanomechanical alterations on 
cortical tissue’s resistance to cracking have not been investigated directly.  Therefore, the present 
study utilized an ovine model for human high-turnover osteoporosis to examine effects of 
antiresorptive treatment on cortical tissue composition, nanomechanical properties, and 
microcrack resistance.  Antiresorptive treatments reduce fracture risk by up to 60%, despite only 
modest increases (from 0 – 8%) in bone mineral density (BMD) [35–37].  This discrepancy 
suggests that tissue-level properties not measureable through macro-scale BMD measures play 
an important role in the reduction in fracture risk with antiresorptive treatments.   
For the current study, treatment effects with a drug from the most widely-prescribed class 
of osteoporosis treatments—bisphosphonates—were compared with effects from another 
antiresorptive agent that acts through endogenous estrogen pathways in bone—a selective 
estrogen receptor modulator (SERM).  Bisphosphonates reduce turnover by incorporating into 
bone matrix in regions of active remodeling and directly inhibiting osteoclastic activity upon 
resorption by these cells [38–41].  Vertebrae from canines treated with clinical doses of 
bisphosphonates have similar strength but reduced energy absorption relative to control animals 
with similar areal BMD, pointing to alterations in nanoscale tissue properties [42].  Indeed, 
cortical tissue from these animals showed increased levels of mineralization and reduced mineral 
heterogeneity after one year of treatment [42,43].  Excessive mineralization coupled with the 
reduced ability to repair microdamage with bisphosphonate treatment may promote the 
development and accumulation of microcracks [14,42]. 
In comparison, SERMs reduce bone turnover by binding to estrogen receptors and acting 
through estrogen response elements and coregulator proteins [44,45].  Bisphosphonates and 
SERMs produce similar reductions in vertebral fracture risk [46], despite reducing bone turnover 
by varying degrees and having distinctly different mechanisms of action.  In canine studies, 
raloxifene enhanced vertebral strength independent of a change in BMD [47], and in vertebral 
cortical bone from rats, raloxifene increased indentation modulus and hardness relative to 
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ovariectomized controls [48].   
The goals of this study were four-fold:  1) examine osteoporosis and treatment-induced 
alterations in nanoscale mechanical properties and tissue composition within osteons and 
interstitial cortical tissue, 2) determine the manner in which changes in tissue composition alter 
nanomechanical function, 3) investigate whether osteoporosis and antiresorptive treatments 
affect the ability of bone tissue to resist microcracking, and, 4) study the contributions of 
nanoscale tissue properties and crack resistance to mechanical function at higher length scales. 
We hypothesized that both bisphosphonate and SERM treatments would increase cortical tissue 
stiffness and hardness relative to osteoporotic tissue through increased mineralization and altered 
mineral and matrix properties.  In a previous study of cancellous tissue from these ewes, 
increased tissue stiffness and hardness with treatment correlated with increased tissue 
mineralization, carbonate substitution in the mineral lattice, and lamellar aligned collagen 
content [49].  Effects in cortical tissue were predicted to be less than those in cancellous tissue 
because cortical tissue is less metabolically active and bisphosphonate uptake is greater in 
cancellous than cortical tissue [50,51].  
 
4.2 Materials and Methods 
The present study utilized cortical tissue from the femora of ewes (Swiss-Ramboulet, aged 6-7 
years at the start of the experiments) subjected to a dietary metabolic acidosis model (MA) for 
human osteoporosis and treated with a SERM, raloxifene (RAL), or a bisphosphonate, 
zoledronate (ZOL).  Effects in cortical bone were examined at the whole bone scale and at the 
bulk and nanoscale tissue levels.   
 
4.2.1 Samples and Specimen Preparation 
Femora were obtained from 25 mature adult ewes (6-7 years old at the start of the experiment) 
from 2 experiments described previously (approved by the Colorado State University 
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Institutional Animal Care and Use Committee) [49].  Originally, the bisphosphonate and SERM 
treatments were planned as a single experiment; however, due to difficulty administering 
alendronate in the first study, the bisphosphonate study was repeated with zoledronate and the 
MA group for comparison.  The first experiment (Experiment 1) had two groups.  Both were fed 
a diet to induce metabolic acidosis for six months followed by another six months of MA with 
either vehicle (MA1, n = 5) or a clinically equivalent dose of raloxifene (RAL, 0.80 mg/kg daily, 
n = 4) administered daily through abomasal cannulae [52,53].  Both treatment groups started 
with n = 6 sheep, based on a power analysis for nanoscale measurements in a pilot study plus one 
additional sheep per treatment group in accordance with standard procedure for ovine 
experiments at Colorado State University.  Two RAL sheep were euthanized early due to 
cannula pull-out and one MA sheep was euthanized due to injuries unrelated to the experiment.  
A group of healthy animals fed a normal diet (CONT, n = 5) were housed in the same facility 
and euthanized in the same season (summer) as Experiment 1.  The second experiment 
(Experiment 2) also had two treatment groups.  Both groups received eight months of MA rather 
than six months due to a delay in receiving the medication for the study.  Subsequently, the 
groups were maintained on the MA diet for an additional 6 months before euthanasia (winter) 
with intravenous administration of either vehicle (MA2, n = 6) or a clinically equivalent dose of 
zoledronate (ZOL, 5 mg/sheep, n = 6) at the beginning of the treatment period.  The second 
experiment included a MA group to compare the effects of zoledronate treatment with the ovine 
osteoporosis model, but did not include a normal diet control group.  After euthanasia, femora 
were stored at -20º C prior to specimen preparation. 
 Whole bone mechanical testing was performed on the right femora.  Left limbs were used 
for bulk mechanical tests of cortical beams (supplementary content, Figure 4.1s), nanoscale 
compositional and mechanical analysis, and indentation fracture tests.  Three millimeter-thick 
transverse sections from the mid-diaphysis were used for nanoscale tissue characterization and 
indentation fracture tests.  Cranial-caudal diameter, medial-lateral diameter, and cortical 
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thickness (average of 4 measurements) were also measured from these transverse sections 
(Image J, NIH, Bethesda, MD). 
 
4.2.2 Whole Bone Mechanical Analysis 
Whole bone mechanical properties were assessed via four-point bending.  The ends of the 
femora were potted with methylmethacrylate (COE tray plastic, GC America, Inc., Alsip, IL) in 
square aluminum tubing to ensure reliable positioning between tests.  The span between pots was 
110 mm for all femora.  For testing, the femora were placed in a four-point bending fixture 
(inner span 130 mm, outer span 210 mm) attached to a servohydraulic material testing machine 
(858 Mini Bionix with Flextest 40 controller, MTS Systems Corporation, Eden Prarie, MN).  The 
fixture contacted the pots rather than the bone directly to reduce stress concentrations and ensure 
that the diaphysis was subjected to a constant bending moment.  Each femur was first loaded 
non-destructively in the medial-lateral, lateral-medial, cranial-caudal, and caudal-cranial 
directions.  These non-destructive tests consisted of ten preconditioning cycles of 10 to 1000 N 
of compression applied at a rate of 7200 N/min.  Finally, the femora were loaded to failure in the 
caudal-cranial direction (caudal aspect subjected to compression and cranial aspect subjected to 
tension) at a rate of 5 mm/min.  Bending stiffness, the slope of the linear portion of the moment-
displacement graph, was determined via linear regression.  For non-destructive tests, the 
regression was performed on the tenth loading cycle.  The failure moment was defined as the 
maximum moment achieved in the destructive test.   
 
4.2.3 Nanoscale Tissue Characterization 
The transverse mid-diaphyseal sections were prepared for nanoscale mechanical testing as 
reported previously [29,49,54].  Sections were fixed, dehydrated, embedded in 
polymethlymethacrylate, and polished anhydrously to a RMS surface roughness of less than 15 
nm on a 5 x 5 µm
2
 AFM Scan (Dimension 3100, Veeco Metrology Group, Plainview, NY) 
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[27,54–56].  Three osteons and three nearby interstitial regions from each sample were selected 
for characterization.  The osteons chosen were quiescent and showed no evidence of remodeling 
activity such as ruffled or enlarged Haversian canals.   
Tissue was characterized at the center of each lamella in a radial line from the center to 
the periphery of the osteons and at five locations in each of the nearby interstitial regions (at 
centers of lamellae if present).  Nanomechanical properties were probed first with 
nanoindentation and then the residual indentations and fiducial markers were used to co-locate 
Raman spectroscopy and second harmonic generation microscopy (SHG) compositional 
measurements.   
 
4.2.3.1 Nanoindentation 
A scanning nanoindenter with a Berkovich diamond tip (Triboindenter, Hysitron, Inc., 
Minneapolis, MN) was used to probe tissue nanomechanical properties within osteons and 
interstitial tissue.  To accurately place indentations at centers of lamellae, surface topography 
scans (20 μm2) were made prior to each indentation [27,29,30,54,56].  The load function 
included a 10 second hold at 700 µN peak load with loading/unloading rates of 50 µN/s [29].  
The resulting indentation depth was approximately 150 nm.  Each osteon contained a mean of 13 
(± 3) lamellae, resulting in roughly 40 osteonal and 15 interstitial measurements (5 per adjacent 
interstitial region) per animal.  Indentation modulus (Ei), a measure of the tissue’s elastic 
properties, and hardness, a measure of inelastic properties, were calculated from the unloading 
portion of the load-displacement curve [57].   
 
4.2.3.2 Raman Spectroscopy 
Tissue composition was characterized with Raman spectroscopy (InVia microRaman, Renishaw, 
Gloucestershire, United Kingdom) at the same locations characterized by nanoindentation 
[29,49].  The spot size was 2 μm2.  For each measurement, Raman peak heights were identified 
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from smoothed spectra after cubic polynomial background subtraction (Matlab, The Math 
Works, Inc., Natik, MA).  Three bone parameters were calculated:  mineral-to-matrix ratio 
(Raman mineral:matrix), B-type carbonate substitution, and crystallinity (Raman crystallinity) 
[29,58–63].  Mineral-to-matrix ratio, a measure of the degree of mineralization of the tissue, was 
calculated as the peak height ratio of the phosphate υ1 (~965 cm-1) to the CH2 wag (~1450 cm
-1
) 
peaks [29,59].  B-type carbonate substitution, a measure of the level of carbonate substitution for 
phosphate in the hydroxyapatite (HA) crystal lattice, was calculated as the peak height ratio of 
the carbonate υ1 (~1070 cm-1) to the phosphate υ1 peak [29,62].  Raman crystallinity, a measure 
of crystal size and perfection, was estimated as the reciprocal of the full width at half maximum 
(FWHM) of the phosphate υ1 peak [29,61,63].  For this measure, a sharper phosphate υ1 peak 
(decreased FWHM) indicates greater mineral crystal size and perfection.   
 
4.2.3.3 Second Harmonic Generation Microscopy (SHG) 
Aligned collagen content was assessed via SHG as described previously (Mai Tai Deep See, 
Spectra Physics; BX61W1, Olympus, Santa Clara, CA ) [29,49].  The pixel size was 0.318 µm
2
.  
A SHG image was taken of each osteon and interstitial region previously characterized with 
nanoindentation and Raman spectroscopy.  The square root of SHG intensity in these images 
equals the concentration of aligned collagen molecules (aligned collagen content) within the 
transverse plane of the sample [64–68].  For each osteon, the aligned collagen content was 
calculated for the radial line across the osteon from center to periphery, resulting in a profile of 
aligned collagen content with distance from the center of the osteon (Matlab, The Math Works, 
Inc.).  The line was 6 pixels wide, corresponding to the Raman spot size of 2 µm.  From this 
profile, maxima corresponding to lamellar aligned collagen and minima corresponding to 
interlamellar aligned collagen were recorded [27].  For each interstitial region, a 20 µm
2
 region 
surrounding the 5 interstitial indents was analyzed.  For this region, the mean and FWHM of 
aligned collagen content were recorded rather than maxima and minima corresponding to 
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lamellar and interlamellar regions because interstitial tissue often did not contain well-defined 
lamellae.   
 
4.2.4 Indentation Fracture Tests 
The relative ability of the cortical tissue to resist cracking was assessed via indentation fracture.  
After analysis with nanoindentation, Raman spectroscopy, and SHG, the transverse sections were 
sputter coated under vacuum with a 10 nm-thick layer of Au-Pd.  Images of 5 osteonal and 5 
interstitial regions were taken at 1000 X magnification with a scanning electron microscope 
(SEM) at an accelerating voltage of 15 keV (Leica Stereoscan 440, Buffalo Grove, IL).  These 
images were used to identify pre-existing cracks.  A microindenter with a custom cube-corner tip 
(Highwood Digital Micro Hardness Tester HWMMT, TTS Unlimited, Inc., Osaka, Japan; Micro 
Star Technologies, Huntsville, Texas) was used to induce cracking [69] in the pre-imaged 
osteonal and interstitial regions by indenting to a peak load of 490 mN with a 10 second hold 
period at peak load.  In preliminary tests, this peak load was reliably produced cracking.  
Indentation depth was over three orders of magnitude greater than the thickness of the Au-Pd 
surface coating for SEM imaging, and cracking behavior was not different between samples 
indented with and without the Au-Pd coating.  After indenting, the regions were re-imaged with 
SEM.  Pre-and post-images were compared to identify new cracks visible on the surface.  
Surface cracks were measured manually via Image J software (NIH, Bethesda, MD).  Four 
outcome measures were recorded for each indentation:  the total amount of cracking, number of 
cracks, mean crack length, and maximum crack length.  The total amount of cracking was the 
sum of all new crack lengths (new cracks plus extensions of pre-existing cracks) created by each 
individual indentation fracture.  The number of cracks was the total number of new cracks and 
crack extensions formed by each indentation fracture.  The mean crack length was the average of 
the crack lengths formed by each indentation fracture.  The maximum crack length was the 
longest crack measured for each indentation fracture. 
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4.2.5 Statistical Analysis 
Statistical analyses were performed separately for Experiment 1 and 2, i.e. RAL was compared 
only with MA1 and CONT, while ZOL was compared only with MA2.  All statistical models 
were linear.  Effects of treatment on whole bone mechanical testing parameters were assessed 
with single-factor ANOVAs with Tukey post-hoc tests.  The significance level was p ≤ 0.05.  
Results stated are significant unless noted otherwise.  Figures display mean values with error 
bars representing 95% confidence intervals. 
Osteonal measurements were analyzed first to determine whether nanomechanical and 
compositional parameters varied across the osteon radii with treatment.  Multi-factor, nested 
ANOVAs with Tukey post-hoc tests determined effects of treatment (CONT, MA, and RAL; 
MA2 and ZOL), distance from the center of the osteon, treatment*distance, sheep (nested), and 
trabeculae (nested).  Next, osteonal and interstitial measurements were analyzed together to 
determine differential effects of treatment between these tissue regions.  Multi-factor ANOVAs 
determined effects of treatment, tissue type (osteonal or interstitial), treatment*tissue type, sheep 
(nested) and trabeculae (nested). 
The contribution of compositional properties (SHG and Raman) to alterations in tissue 
nanomechanical properties was determined by multiple linear regression analysis. The mean 
values for the compositional and nanomechanical parameters were calculated for each osteon.  
Correlating these averaged values rather than each individual measurement location reduced 
variability from inherent heterogeneity of the bone tissue or slight misalignment between 
measurement locations.  Correlations were performed separately for Experiment 1 and 
Experiment 2.  First, ANOVA models were performed for Ei and H vs.  mineral-to-matrix ratio, 
B-type carbonate substitution, crystallinity, lamellar aligned collagen, and treatment, allowing 
the relationships between compositional and nanomechanical parameters to vary with treatment.  
Subsequently, non-significant terms were removed from the model stepwise in order of 
decreasing p-value until only significant effects remained.  Finally, all compositional parameters 
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were removed leaving only treatment.  Thus, the added explanatory power of the significant 
compositional measures over a model with treatment alone could be determined.  For significant 
improvement in explanatory power, a minimum 5% increase in the R
2
 value was considered 
statistically significant. 
The effects of treatment on micro-cracking were also assessed with multi-factor 
ANOVAs with Tukey post-hoc testing.  Model parameters included treatment (CONT, MA, and 
RAL; or MA2 and ZOL), tissue type (osteonal or interstitial), treatment*tissue type, and sheep 
(nested).  
 
4.3 Results 
 
4.3.1 Whole Bone Mechanical Analysis 
Zoledronate but not raloxifene improved whole bone mechanical performance relative to the MA 
model (Figures 4.1).  MA did not alter whole bone mechanical performance relative to control 
animals.  Zoledronate increased whole bone bending stiffness by 30% and failure moment by 
49% in the cranial-caudal direction over MA in whole bone non-destructive and failure tests of 
the diaphysis (Figure 4.1).  Mid-diaphyseal cortical diameter, thickness, and area were not 
different between treatment groups (Appendix 1).   
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4.3.2 Nanoscale Tissue Characterization 
Indentation modulus, hardness, and aligned collagen content decreased in the cortical tissue of 
MA ewes relative to controls (Figure 4.2).  The decrease in indentation modulus depended on the 
tissue type and was 8.5% in osteons and 12% in interstitial tissue.  Hardness decreased by 10% 
independently of tissue type.  Within osteons, lamellar aligned collagen decreased by 18% and 
interlamellar aligned collagen decreased by 11% with MA relative to controls (Figure 4.3).  
Interstitial aligned collagen and crystallinity did not vary with MA. 
Raloxifene restored indentation modulus, hardness, and lamellar aligned collagen to 
control levels in osteonal tissue (Figures 4.2 and 4.3).  In interstitial tissue, only hardness was 
fully restored to control levels.  Indentation modulus increased by 9.2%in osteons with 
raloxifene relative to MA and was equal to that of controls, while interstitial indentation modulus 
increased by 7.3% relative to MA but was still 5.0% below control levels.  Hardness increased 
9.5% with raloxifene and reached control levels regardless of tissue type.  Within osteons, 
lamellar aligned collagen increased by 22% relative to MA to reach control levels (Figure 4.3).   
 
Figure 4.1 Whole bone mechanical testing results from four-point bending tests to failure in the 
cranial-caudal direction.  Zoledronate increased both bending stiffness and failure moment relative to 
the MA model.  * p < 0.05 
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Interlamellar aligned collagen also increased relative to MA (+10%) and was restored to control 
levels.   
 Zoledronate increased indentation modulus and hardness in osteons and interstitial 
regions relative to MA (Figure 4.2).  Indentation modulus increased by 3.6% and hardness 
increased by 6.9%, regardless of tissue type.  Aligned collagen content did not vary with 
zoledronate (Figure 4.3).  Alterations in Raman compositional parameters with MA, raloxifene, 
and zoledronate were minimal (supplementary content, Figure 4.2s). 
Figure 4.2  Nanomechanical testing results by treatment for osteonal and interstitial tissue.  Both 
raloxifene and zoledronate increased indentation modulus and hardness relative to the MA model.  
Solid bars = lamellar osteonal tissue.  Osteonal properties were fully restored to CONTROL levels.  
Open bars = interstitial tissue.  A = different from CONTROL.  B = different from MA.  * = different 
from osteonal tissue.  
#
 = effects of treatment varied by tissue type. 
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4.3.3 Correlations between Nanoscale Composition and Nanomechanical Parameters 
For Experiment 1 (CONT, MA1, and RAL), indentation modulus and hardness correlated with 
B-type carbonate substitution, lamellar aligned collagen, and crystallinity, and indentation 
modulus additionally correlated with mineral-to-matrix ratio (Table 4.2, Figure 4.6).  
Compositional parameters alone explained only 21% of the variation in indentation modulus and 
did not significantly predict variations in hardness.  Allowing compositional relationships to vary 
with treatment improved the predictive values of the models to 48% for indentation modulus and 
19% for hardness.  The positive relationship between indentation modulus and mineral-to-matrix 
ratio was independent of treatment (5% explanatory power).  Though small in magnitude 
(supplementary content, Figure 4.2s), alterations in B-type carbonate substitution explained 36% 
of the variation in indentation modulus with MA and 10% of the variation in hardness in 
controls.  In other treatment groups, B-type carbonate substitution did not significantly predict 
nanomechanical variations. The positive correlation with crystallinity predicted 14% of the 
variation in indentation modulus and 12% of the variation in hardness in control and MA animals 
Figure 4.3  Aligned collagen content by treatment for interlamellar and lamellar osteonal tissue and 
interstitial tissue.  Gray bars = interlamellar osteonal tissue.  Black bars = lamellar osteonal tissue.  
Open bars = interstitial tissue (average over 20 µm
2
 area surrounding indentations).  A = different 
from CONTROL.  B = different from MA.  
+
 = different from interlamellar osteonal tissue.  * = 
different from lamellar osteonal tissue.  
#
 = effects of treatment varied by tissue type. 
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Nanomechanical         
Parameter 
Composition 
Only Treatment + Composition 
Experiment 1 R2 R2 Significant Parameters 
Indentation Modulus 0.21 0.48 
Mineral:matrix 
B-type carbonate substitution+ 
Crystallinity+ 
Lamellar aligned collagen 
Hardness N.S. 0.19 
B-type carbonate substitution+ 
Crystallinity+ 
Lamellar aligned collagen+ 
Experiment 2     
Indentation Modulus N.S. 0.11 
B-type carbonate substitution+ 
Crystallinity 
Hardness N.S. 0.09 B-type carbonate substitution+ 
but did not predict nanomechanical parameters within RAL-treated animals.  Lamellar aligned 
collagen explained 26% and 19% of the variation in hardness in controls and MA animals, 
respectively, but was not a predictor for hardness within RAL-treated animals. 
  
Table 4.1  Coefficients of variation (R
2
) for osteonal nanomechanical properties modeled as linear 
functions of compositional parameters.  “Composition Only” indicates the explanatory power of the 
linear models with significant compositional parameters only (p < 0.05).  “Composition + 
treatment” indicates the explanatory power of the models with significant compositional parameters, 
treatment, and the effects of treatment on the nanomechanical relationships with composition.  
+
 
Indicates compositional parameters whose effects varied with treatment.  An increase in R
2
 > 0.05 is 
considered a meaningful improvement. 
 110 
 
   
  
Figure 4.4  Measured nanomechanical parameters vs. predicted values from the compositional 
ANOVA models for each experiment (Table 2).  Relationships between nanomechanical and 
compositional parameters were allowed to vary between treatment groups.  
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 For Experiment 2 (MA2 and ZOL), composition alone did not predict variations in 
nanomechanical parameters because compositional relationships depended on treatment.  B-type 
carbonate substitution predicted 31% and 39% of the variation in indentation modulus and 
hardness with MA, respectively, but predicted less than 5% of the nanomechanical variations in 
zoledronate-treated animals.  The explanatory power of the models for indentation modulus and 
hardness was much poorer for Experiment 2 than for Experiment 1.   
 
4.3.4 Indentation Fracture Tests 
Cracks formed during cube-corner indentation were classified into three main types:  
circumferential cracking and deformation immediately around the indentations, radial cracks 
extending outward from the indentations, and cracks extensions from nearby stress concentrators 
such as osteocytes or pre-existing cracks (Figures 4.7 and 4.8).  The total amount of cracking 
around the indentations did not vary between treatment groups; however, the mean crack length 
was 45% longer in MA1 than in control sheep (Figure 4.9).  Raloxifene reduced the mean crack 
length relative to MA (-20%), but the mean length was still greater than that present in controls 
(+17%).  From visual inspection, the increased crack length in MA1 sheep was due to more 
radial cracking that extended farther from the indentations.  In contrast to raloxifene, zoledronate 
did not have any effect on mean crack length relative to MA animals.   
 Interstitial tissue had a greater total amount of cracking in both experiments due to both 
increased numbers of cracks and extended crack lengths.  The total amount of cracking was 18% 
and 29% greater in interstitial tissue than in osteons in Experiments 1 and 2, respectively.  For 
Experiment 1, the maximum crack length was 12% longer for interstitial tissue than osteons and 
interstitial tissue trended towards having increased numbers of cracks (+10%, Appendix 1).  In 
Experiment 2, interstitial cracks had a greater mean crack length (+8%) and trended towards 
increased maximum crack length (+10%) relative to osteons.  Interstitial tissue also had greater 
numbers of cracks in Experiment 2 (+21% vs. MA2).   
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Figure 4.5  SEM images of osteons taken before (A,C) and after (B,D) indentation fracture for a sheep 
from MA1 (A, B) and raloxifene (C, D) treatment groups. Dark areas are Haversian canals and 
osteocyte lacunae.  Cracks and some edges around Haversian canals and osteocyte lacunae appear 
white due to edge brightening from the SEM.  Several crack behaviors are evident:  cracks deflected 
along lamellae and cement lines (solid black arrow), and extended from stress concentrators such as 
Haversian canals (outlined black arrow), osteocytes (solid white arrows), and pre-existing cracks 
(outlined white arrow). 
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Figure 4.6  SEM images of interstitial regions taken before and after indentation fracture for a sheep 
from (A,B) MA1, and (C,D) raloxifene treatment groups.  Dark areas are osteocyte lacunae.  Cracks 
and edges around some osteocyte lacunae appear white due to edge brightening from the SEM.  
Cracking/crushing around sides of indentations was evident (solid black arrows) as well as cracks 
extending radially away from the indentations and crack extensions from stress concentrators such as 
osteocytes or pre-existing cracks (hollow black arrows).  Cracks initiated from osteocytes but were 
also arrested by osteocytes. 
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4.4 Discussion 
At the nanoscale, six months of treatment with either raloxifene or zoledronate reversed the 
degradation in cortical nanomechanical properties in an ovine model for human high-turnover 
osteoporosis.  Raloxifene restored indentation modulus and hardness to control levels in osteons 
and also increased these properties in interstitial tissue.  Alterations in all four compositional 
parameters—mineral-to-matrix ratio, B-type carbonate substitution, lamellar aligned collagen 
and crystallinity—explained nearly 50% of the variation in indentation modulus in control, MA, 
and raloxifene-treated ewes.  Alterations in all but mineral-to-matrix ratio explained up to 20% 
of the variations in hardness.  B-type carbonate substitution and lamellar aligned collagen 
provided the majority of the predictive power for both models.  Nanomechanical properties with 
MA2 and zoledronate also correlated with alterations in B-type carbonate substitution, with the 
relationships depending on treatment; however, the predictive power of the models was limited. 
 
Figure 4.7  Indentation fracture results by treatment for osteons and interstitial regions.  The total 
amount of cracking (sum of all crack lengths) was greater in interstitial than osteonal tissue but did 
not vary between treatment groups.  The mean crack length was greater with MA1 than CONTROL 
and was reduced relative to MA1 with raloxifene treatment to reach levels equivalent to control.  
Treatment affected osteonal and interstitial tissue similarly.  Solid bars = osteonal regions.  Open 
bars = interstitial regions.  A = different from CONTROL.  B = different from MA.  * = different from 
osteonal tissue.   
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 Cortical nanomechanical improvements with raloxifene were similar to those seen 
previously in cancellous tissue from these animals; however, improvements with zoledronate 
were markedly less in cortical tissue (supplementary content, Table 4.1s) [49].  In both 
cancellous and cortical bone, raloxifene increased tissue stiffness and hardness by nearly 10% 
relative to MA.  Raloxifene acts through the natural estrogen receptor pathways present in bone 
[44,45] and consequently seems to produce relatively uniform nanomechanical effects 
throughout cancellous and cortical bone tissue.  In comparison, zoledronate increased stiffness 
and hardness, respectively, by 12 and 16% in cancellous tissue (near the surfaces of trabeculae), 
but only increased these properties by 3.5 and 6.9% in cortical tissue.  Bisphosphonate uptake is 
greater in cancellous than cortical bone due to the greater surface area and number of active 
remodeling sites where the drugs preferentially incorporate [50,51].  Bisphosphonates provide 
less improvement in BMD in the peripheral skeleton, where the proportion of cortical to 
cancellous bone is greater than in the central skeleton [70].   
Mineralization and tissue stiffness became more uniform throughout cortical tissue with 
the MA model.  In Experiment 1, interstitial tissue was more mineralized and stiffer than 
osteonal tissue in healthy animals, but had equivalent mineralization and stiffness to osteons with 
MA (Figures 4.1 and supplementary content, Figure 4.2s).  Additionally, the positive gradients in 
mineralization, stiffness, and mineral crystallinity from center to periphery of osteons present in 
healthy ewes were no longer present with MA (supplementary content, Table 4.2s).  The 
increased homogeneity in osteoporotic tissue is well documented [71–74], and the present results 
show the manner in which this homogenization occurs spatially within the osteons and interstitial 
tissue of an ovine model of post-menopausal osteoporosis.  Computational modeling suggests 
that nanoscale mechanical heterogeneity promotes energy dissipation [18,19].  The osteonal 
structure of cortical bone and the ratio of interstitial to osteonal mechanical properties influence 
crack behavior and fracture toughness [20–24]. 
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 The total amount of cracking associated with indentation fracture did not vary between 
treatment groups; however, treatment did affect cracking behavior.  The mean crack length was 
greater with MA than in healthy sheep, indicating that the cortical tissue was less able to 
withstand crack growth once cracking was initiated.  Interestingly, MA ewes had less aligned 
collagen content within osteons, and collagen fiber bridging is a known toughening mechanism 
in bone that acts to prevent the elongation of cracks [75].  With raloxifene, aligned collagen 
content was restored to control levels and crack length decreased.  Other toughening mechanisms 
common to bone were also observed in this experiment, such as uncracked ligament bridging and 
crack deflection along cement lines and lamellae in osteons (Figures 4.7 and 4.8) [75].  In 
comparison with raloxifene, no improvements in crack length or number were observed relative 
to MA sheep with zoledronate treatment.  Beagles treated for three years with a clinical dose of 
bisphosphonates showed no difference in crack density or numbers but had increased crack 
length relative to healthy animals [42].  In this study, six months of zoledronate did not increase 
crack length or the total amount of cracking in comparison with a model more representative of 
human osteoporosis.   
Older, interstitial cortical tissue was more mineralized and harder than younger, osteonal 
tissue and showed an increased propensity for cracking.  Interstitial tissue had both greater 
numbers of cracks—indicating decreased resistance to microcrack formation—and longer 
cracks—indicating decreased resistance to crack propagation once initiated.  Similar increases in 
tissue age and mineralization with the long-term suppression of remodeling (as with long-term 
bisphosphonate treatment) may result in tissue less able to prevent crack initiation and 
propagation.   
Although raloxifene produced greater effects than zoledronate at the nanoscale, only 
zoledronate increased bending stiffness and failure moment in whole bone tests relative to the 
osteoporosis model.  Stiffness and strength also increased with four months of bisphosphonate 
treatment in the tibiae of ovariectomized rats [76].  No increase in stiffness or strength was 
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observed in the beagle ribs; however, the beagles were not osteopenic or osteoporotic and 
differences could exist between the femur and the rib, a non-load-bearing site [42].  In the 
current study, a trend towards increased bulk tissue stiffness was observed with zoledronate but 
not raloxifene relative to the MA model in apparent-level bending tests of cortical beams 
(supplementary content, Figure 4.1s).  Similarly, one year of treatment with a clinical dose of 
raloxifene did not alter the strength or stiffness of cortical beams machined from beagle femora 
[77].  In both the present study and the beagle stud, animals were ovary-intact and had replete 
levels of estrogen that could blunt the effects of raloxifene.  Raloxifene improved post-yield 
behavior in cortical tissue loaded in bending [77]; however, the ovine whole bone and apparent-
level cortical tests in the present study had little post-yield behavior, which precluded 
comparison between studies. 
Changes in Raman compositional parameters in cortical tissue were less pronounced than 
those observed previously in cancellous bone from these ewes (supplementary content, Table 
4.1s) [49].  Cortical compositional alterations were expected to be less pronounced due to the 
lower metabolic activity in cortical bone and the aforementioned bisphosphonate targeting to 
cancellous tissue.  Furthermore, the limited explanatory power of some of the nanomechanical 
versus compositional correlations and the fact that some compositional relationships varied 
between treatment groups indicates that additional compositional factors not measured in this 
study also play an important role in mechanical function.  These factors could include non-
enzymatic collagen cross-links, accumulation of advanced glycation end-products, mineral 
crystal orientation, and non-collagenous proteins [43,78,79]. 
Several limitations could affect the interpretation of our results.  Previously in the MA 
model, adaptive changes were seen in cortical bone after six months of exposure to the acidifying 
diet [80].  BMD of the femur showed little change because the decrease in cancellous BMD was 
accompanied by an increase in BMD in the diaphysis.  In the current study, mineral-to-matrix 
ratio in the cortical tissue of the mid-diaphysis of the femur increased slightly with MA relative 
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to healthy ewes (supplementary content, Figure 4.2s), consistent with these adaptive changes.  
Additionally, the range of the nanoscale data for Experiment 2 was quite small due to the smaller 
changes in cortical tissue properties with zoledronate.  The small range of the data likely 
contributed to the limited explanatory power of the nanomechanical vs. compositional 
correlations for Experiment 2.   
A few methodological limitations are also worth noting.  First, the sample size of the 
large animal model was adequately powered for nanoscale measurements that benefit from 
repeated measures, but the sample size was underpowered for bulk tissue characterization.  
Additionally, large variations in bulk tissue measures between animals affected our ability to 
detect treatment effects; therefore, the lack of bulk-level effects reflects a combination of lower 
resolution and inadequate sample size.  Secondly, nonconcurrent performance of the two 
experiments of this study prevented direct statistical comparison between all treatment groups.  
Ideally, controls would have been included as part of the Experiment 1 design; however, animals 
were housed in the same facility and euthanized in the same season.  The delay in administering 
zoledronate in Experiment 2 prolonged the MA period by two months.  Also, animals in 
Experiment 2 were euthanized in a different season than Experiment 1 (winter vs. summer, 
respectively).  Both factors could produce differences between the two MA groups at the start of 
treatment, which might influence treatment effectiveness.  Consequently, direct comparisons 
between Experiment 2 and both Experiment 1 and controls were avoided.   A limitation of our 
characterization was that fluorochromes were not administered to the animals and hence newly 
formed osteons could not be identified.  Previously, zoledronate increased mineralization and 
mineral crystallinity in newly formed tissue in cancellous bone [81].  Future study with 
fluorochrome labeling to indicate osteon age will allow full characterization of spatial nanoscale 
changes within newly formed osteons with treatment.   
Finally, the SEM crack imaging of the indentation fracture experiment only allowed 
visualization of surface cracks and did not allow analysis of sub-surface damage or cracks that 
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deflected in the longitudinal direction of the bone.  In addition, whether or not cracks visible on 
the surface were connected sub-surface could not be determined.  Error could also arise from the 
subjective nature of measuring the cracks manually.  However, the microcrack measurement was 
performed by a single individual with all samples measured consistently.  Thus, artifacts due to 
measurement error were minimized and treatment effects could be compared because all samples 
were characterized in the same manner. 
 In conclusion, six months of raloxifene or zoledronate treatment improved tissue 
nanomechanical properties in osteons and interstitial cortical tissue in an ovine model for human 
high-turnover osteoporosis.  Raloxifene acts through the natural estrogen receptor pathways in 
bone and produced similar changes in the cortical and cancellous tissue of the sheep femora.  In 
contrast, tissue effects with zoledronate were more pronounced in cancellous bone where 
bisphosphonates preferentially incorporate.  Zoledronate improved the stiffness of bulk cortical 
tissue and whole bone stiffness and strength, while raloxifene improved the ability of cortical 
tissue to resist microcrack elongation.  Older, more highly mineralized interstitial tissue in the 
cortex showed an increased propensity for crack initiation and propagation relative to osteonal 
tissue.  Thus, the long-term suppression of bone remodeling with bisphosphonate treatment may 
result in cortical tissue more prone to microcracking.   The results of the present study suggest 
that combined or sequential treatment with bisphosphonates and SERMs could potentially 
combine the best aspects of each treatment—the ability to quickly improve strength and stiffness 
with zoledronate, followed by an improvement in crack resistance provided by raloxifene.  
Combined bisphosphonate/SERM treatment is known to provide greater improvements in BMD 
over either therapy, alone, and sequential treatment with SERMs after bisphosphonates preserves 
gains in BMD better than bisphosphonate withdrawal without additional treatment [82].  Thus, 
the effects of combined or sequential treatment improving tissue microcrack initiation and 
propagation warrants further investigation.  
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CHAPTER 4 SUPPLEMENTARY CONTENT 
APPARENT LEVEL MECHANICAL TESTS OF CORTICAL BEAMS AND NANOSCALE 
RAMAN COMPOSITIONAL CHARACTERIZARION 
Supplementary Methods for Figure 4.1s. 
Bulk cortical tissue properties were assessed via three-point bending tests of rectangular cortical 
beams taken from the lateral aspect of the distal femur just below the mid-diaphysis.  Three mm-
wide longitudinal sections were excised from the lateral aspect of the distal femoral shaft using a 
Figure 4.1s  Bulk tissue mechanical testing results from three-point bending tests of cortical beams.  
Flexural modulus trended towards an increase with zoledronate relative to the MA model (+ 12%,  p 
= 0.08).  MA and raloxifene did not alter whole bone or bulk tissue properties relative to controls   
+ 
p < 0.10 
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precision diamond saw (IsoMet 1000, Buehler, Lake Bluff, IL).  Sections were polished to a 2 
mm-square cross section with 30 µm and 15 µm lapping films (MetaServ 250, Buehler, Lake 
Bluff, IL) and the length was cut to 25 mm (IsoMet).  Ethylene glycol was used as a lubricant for 
polishing to prevent mineral leaching [1].  The beams were wrapped in saline soaked gauze and 
stored at -20˚C prior to testing.  
 The cortical beams were tested with servohydraulic material testing machine (858 Mini 
Bionix) with a 445 N load cell (SSM-100, Transducer Techniques, Temecula, CA).  The span 
between the two outer supports of the testing fixture was 20 mm.  To reduce local deformation at 
the contact-points, 3 mm
3
 metal blocks were adhered to the periosteal surface of the beams via a 
positioning fixture that ensured 20 mm spacing between blocks.  Beams were positioned for 
testing with the lower supports in contact with the metal blocks, placing the periosteal side of the 
beams in tension during the tests.  A linearly variable differential transformer (LVDT) 
(LBB375PA-100, Measurement Specialties, Hampton, VA) mounted in the base of the three-
point bending fixture measured beam deflection mid-span during the tests.  Beams were tested to 
failure at a deflection rate of 5 mm/min.  The bending modulus (EB), flexural strength (σf), strain 
at failure (ε), and energy to failure (EF) of the cortical beams were determined from the load-
displacement data.  Effects of treatment on these outcome measures were assessed with single-
factor ANOVAs with Tukey post-hoc tests.   
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Figure 4.2s  Raman compositional parameters by treatment for osteonal and interstitial tissue.  
Changes in Raman compositional parameters in cortical tissue with MA and treatments were minimal.  
Solid bars = osteonal tissue.  Open bars = interstitial tissue.  A = different from CONTROL.  B = 
different from MA.  * = different from osteonal tissue.  
#
 = effects varied by tissue type. 
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Table 4.1s  Percentage change in compositional and nanomechanical parameters with treatment in 
cancellous [2] and cortical bone.  If changes with treatment varied by region (superficial, intermediate 
or central in cancellous bone; osteonal or interstitial in cortical bone), then percent changes are listed 
for each region separately.  S = superficial region; I = intermediate region in cancellous/interstitial 
region in cortical; C = central region; O = osteonal region. 
 Cancellous Tissue  Cortical Tissue  
Parameter Treatment vs. CONT vs. MA vs. CONT vs. MA 
Indentation 
Modulus (GPa)  
MA1 -15 O: -8.5 
I: -12 
RAL -6.5 +9.6 O: N.S. 
I: -5.0 
O: +9.2 
I: +7.3 
ZOL S: +12 
I: N.S. 
C: N.S. 
+3.5 
Hardness (GPa) MA1 -13 -10 
RAL -4.6 +9.9 N.S. +9.5 
ZOL S: +16 
I: N.S. 
C: N.S. 
+6.9 
Mineral:Matrix  MA1 N.S. O: +4.2 
I: N.S. 
RAL N.S. N.S. O: +5.6 
I: N.S. 
O: N.S. 
I: N.S. 
ZOL S: +10 
I: N.S. 
C: N.S. 
O: N.S. 
I: +4.1 
B-Type Carbonate 
Substitution  
MA1 S: -11 
I: -11 
C: N.S 
O: -3.1 
I: -2.3 
RAL S: -14 
I: -10 
C: N.S. 
N.S. O: N.S. 
I: -3.9 
O: +2.3 
I: N.S. 
ZOL +4.7 +1.4 
Crystallinity (cm-1)   MA1 N.S. N.S. 
RAL N.S. N.S. N.S. +0.56 
ZOL N.S. -0.45 
Lamellar Aligned 
Collagen  
MA1 +2.6 -18 
RAL +4.6 N.S. N.S. +22 
ZOL -13 N.S. 
Interlamellar 
Aligned Collagen  
MA1 N.S. -11 
RAL +6.6 +4.6 N.S. +10 
ZOL -12 N.S. 
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                          Experiment 1 
Outcome Parameter:   CONT ALL MA1 RAL ALL MA2 ZOL 
Indentation Modulus  15 3.0+ 7.2 5.5 
Hardness 5.8 N.S. 
Mineral:Matrix  11 N.S 7.4 5.0 
B-Type Carbonate Substitution 3.1 N.S. 
Crystallinity 11 N.S. N.S. 5.2 N.S. 
Lamellar Aligned Collagen 25 30 
Interlamellar Aligned Collagen 20 23 
Experiment 2  
Table 4.2s  Percentage increase in nanomechanical and compositional parameters from the center to 
the periphery of the average osteon.  Average osteon radius = 150 µm.  The “ALL” column denotes 
gradients that were independent of treatment type.  If gradients were dependent on treatment, then 
results are listed individually by treatment group.  p < 0.05 unless indicated by 
+
.  
+
 = p < 0.1 
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
 
The objectives of this research were to determine variations in tissue composition and 
nanomechanical properties within the microstructures of cortical and cancellous bone with 
ageing, osteoporosis, and antiresorptive treatment, correlate tissue composition with 
nanomechanical function, and examine the effects of these tissue property changes on 
microcracking resistance and mechanical performance at higher length scales.  Tissue stiffness 
and hardness followed changes in mineral and matrix properties with the natural ageing process 
and increased sharply in young, growing animals while remaining relatively constant after sexual 
maturity.  Both the bisphosphonate, zoledronate, and the SERM, raloxifene, improved tissue 
nanomechanical function in a model of high-turnover osteoporosis, with zoledronate effects 
localized at surfaces of trabeculae while raloxifene effects were uniform throughout cortical and 
cancellous tissue.  Tissue-level alterations with raloxifene improved cortical resistance to 
microcrack elongation while alterations with zoledronate led to improved stiffness and hardness 
at higher length scales.  Understanding these relationships will improve our understanding of 
normal and pathological bone function and may enable us to improve upon current therapies for 
skeletal diseases. 
 
5.1 Nanoscale Material Alterations in Bone with Ageing 
The gradient in tissue age from center to periphery of osteons was utilized to examine tissue 
material property changes resulting from the natural ageing process in a baboon model for 
human ageing.  Tissue compositional and nanomechanical alterations were studied with tissue 
age across osteons and animal age within baboons of different ages covering the entire lifespan.  
Indentation modulus and hardness followed biphasic relationships with animal age, following 
trends in mineral-to-matrix ratio, carbonate substitution, and the ratio of lamellar to interlamellar 
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aligned collagen, which increased sharply during rapid growth in young animals and then leveled 
off after sexual maturity.  Across the osteon radii, carbonate substitution, crystallinity, and the 
ratio of lamellar to interlamellar aligned collagen increased with tissue age.  These results were 
the first to demonstrate the relationships with tissue and animal age over an entire lifespan, as 
previous studies have produced mixed results due to their focus on small numbers of mature, 
aged subjects [1–4].  The positive relationships between nanomechanical properties and tissue 
mineralization, carbonate substitution, and collagen content and organization demonstrated 
previously in rodent models and small numbers of human vertebrae [5–8] held over the entire 
lifetime of a closely-related non-human primate.  Additionally, mineral-to-matrix ratio 
effectively captured variations in nanomechanical parameters explained by both mineral (b-type 
carbonate substitution) and matrix (lamellar aligned collagen) components bone tissue.  Mineral-
to-matrix ratio explained 78% of the variation in indentation modulus and 70% of the variation 
in hardness with ageing.   
 A strength of this study was that the baboons were part of a primate colony without 
experimental intervention.  Therefore, their bone tissue presents an accurate picture of the 
skeletal changes that naturally occur over a lifetime.  As a closely related primate, baboons have 
similar bone microstructure and follow a similar progression with ageing as humans, including 
reproductive senescence and menopause accompanied by changes in hormone levels that are 
important in bone metabolism and loss [9–12].  However, a significant limitation of this 
approach was that animals were not injected with fluorochromes and therefore osteon age could 
not be readily determined.  The osteons chosen for characterization were not visibly in the 
process of remodeling.  In the future, fluorochrome labeling to identify new osteons will allow 
the full effects of tissue age within osteons to be determined.  Newly formed osteons would be 
expected to have tissue properties similar to young, sexually immature animals from this study, 
with lower stiffness and hardness associated with lower levels of mineralization, carbonate 
substitution, crystallinity, and aligned collagen content.  Additionally, studies of male animals 
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will allow identification of sex-based differences.  Finally, relationships between the age-related 
changes in tissue material properties observed in this study and the resistance to damage and 
microcracking should be determined.  Bulk and whole-bone fracture toughness is known to 
decrease with ageing [13,14], and ultimately the failure of bone starts with crack initiation and 
propagation at the tissue-level.  Indentation fracture tests such as the methods developed for Aim 
3 of this thesis could be used to identify relationships between age-related tissue property 
changes and the ability of the tissue to resist microcrack initiation and propagation.   
 
5.2 Alterations with Osteoporosis and Antiresorptive Treatment 
Once variations in nanoscale material properties with the natural ageing process were 
established, pathological alterations with osteoporosis and antiresorptive treatment were 
documented in a large ovine study utilizing a dietary model for human high-turnover 
osteoporosis.  In cancellous tissue, six months with antiresorptive treatment—the 
bisphosphonate, zoledronate, or the SERM, raloxifene—improved tissue nanomechanical 
properties in the distal femur relative to the osteoporosis model.  Zoledronate improved tissue 
stiffness and hardness at the surfaces of trabeculae, where bisphosphonates are known to 
incorporate into regions of active remodeling [15–20].  Nanomechanical improvements with 
raloxifene were of lesser magnitude (percentage increase) than those with zoledronate and were 
distributed throughout trabeculae rather than focused exclusively near surfaces.  
Unlike nanoscale techniques, measurements of bulk cancellous properties detected few 
alterations with the osteoporotic model and treatment.  Not only do bulk tissue measures lack the 
spatial resolution of nanoscale techniques, but they also do not have the ability for repeated 
measures to improve power.  Based on a power analysis, the sample size for the bulk tissue 
measurements of the ovine study would need to increase three-fold for trends in BV/TV and 
Tb.Th and to become significant.  The nanoscale improvements in tissue stiffness did produce 
substantial increases in the estimated bending stiffness of individual trabeculae.  Future study 
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with a larger sample size appropriately powered for bulk tissue and whole bone measures would 
definitively determine whether the nanomechanical improvements observed here with 
antiresorptive treatment produce improvements at higher length scales.  Bulk tissue and whole 
bone testing in beagles with zoledronate and raloxifene do suggest that there are contributions to 
whole bone strength from tissue-level alterations [21,22].  Other aspects of tissue-level 
mechanical function not measured with the nanoindentation experiments here could also play an 
important role in bulk and whole bone mechanical function and fracture resistance.   For 
example, the interlamellar or interface regions between lamellae could be particularly important 
because shearing or cracking of these regions could compromise the composite structure.  
Indeed, microcracks in cancellous bone appear to form parallel to the lamellar structure within 
trabeculae, possibly along these interface regions.  Additionally, the amount of these microcracks 
was increased with bisphosphonate treatment in the beagle studies [23–25]. 
In cortical tissue, raloxifene and zoledronate also improved nanomechanical properties in 
osteons and interstitial regions relative to the MA osteoporosis model.  In contrast to cancellous 
tissue, improvements in cortical tissue stiffness and hardness were greater with raloxifene than 
with zoledronate.  By acting through the natural estrogen receptor pathways in bone, raloxifene 
affected both cancellous and cortical tissue similarly, increasing stiffness and hardness in both 
tissues by roughly 10% over the osteoporotic model (Tables 5.1, 5.2).  Increases in cortical 
nanomechanical properties with zoledronate were less than half of those that occurred at the 
surfaces of trabeculae in cancellous bone.  Bisphosphonate uptake is greater in cancellous than in 
cortical tissue, and again these results indicate that zoledronate produces the greatest 
improvements in regions where bisphosphonates preferentially incorporate [26,27].   
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Cancellous Tissue  Cortical Tissue  
Parameter Treatment vs. CONT vs. MA vs. CONT vs. MA 
Indentation 
Modulus (GPa)  
MA1 -15 O: -8.5 
I: -12 
RAL -6.5 +9.6 O: N.S. 
I: -5.0 
O: +9.2 
I: +7.3 
ZOL S: +12 
I: N.S. 
C: N.S. 
+3.5 
Hardness (GPa) MA1 -13 -10 
RAL -4.6 +9.9 N.S. +9.5 
ZOL S: +16 
I: N.S. 
C: N.S. 
+6.9 
Mineral:Matrix  MA1 N.S. O: +4.2 
I: N.S. 
RAL N.S. N.S. O: +5.6 
I: N.S. 
O: N.S. 
I: N.S. 
ZOL S: +10 
I: N.S. 
C: N.S. 
O: N.S. 
I: +4.1 
B-Type Carbonate 
Substitution  
MA1 S: -11 
I: -11 
C: N.S 
O: -3.1 
I: -2.3 
RAL S: -14 
I: -10 
C: N.S. 
N.S. O: N.S. 
I: -3.9 
O: +2.3 
I: N.S. 
ZOL +4.7 +1.4 
Crystallinity (cm-1)   MA1 N.S. N.S. 
RAL N.S. N.S. N.S. +0.56 
ZOL N.S. -0.45 
Lamellar Aligned 
Collagen  
MA1 +2.6 -18 
RAL +4.6 N.S. N.S. +22 
ZOL -13 N.S. 
Interlamellar 
Aligned Collagen  
MA1 N.S. -11 
RAL +6.6 +4.6 N.S. +10 
ZOL -12 N.S. 
Table 5.1 Percentage change in compositional and nanomechanical parameters with 
treatment in cancellous and cortical bone.  If treatment changes varied by region (superficial, 
intermediate or central in cancellous bone; osteonal or interstitial in cortical bone), then 
percent changes are listed for each region separately.  S = superficial region; I = 
intermediate region in cancellous/interstitial region in cortical; C = central region; O = 
osteonal region. 
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Cancellous Tissue  Cortical Tissue  
Parameter Treatment Superficial Intermediate Central Osteonal Interstitial 
Indentation 
Modulus (GPa)  
CONT 27.1 ± 1.2 28.7 ± 0.9S 29.5 ± 0.8S 30.6 ± 0.6  31.9 ± 0.6O 
MA1 23.2 ± 1.7* 24.1 ± 1.4*S 25.4 ± 1.3*S 28.0 ± 0.7* 28.2 ± 0.9* 
RAL 24.8 ± 1.7*+ 27.5 ± 1.3*+S 27.2 ± 1.8*+S 30.6 ± 0.7* 30.3 ± 1.2*+ 
MA2 24.5 ± 1.1 26.8 ± 1.1S 26.9 ± 0.8S 31.2 ± 0.5 30.6 ± 0.6 
ZOL 27.5 ± 1.3+ 26.3 ± 1.0S 27.0 ± 0.8 31.8 ± 0.6+ 32.2 ± 0.7+ 
Hardness (GPa) CONT 1.09 ± .06 1.09 ± 0.05 1.14 ± 0.05S 1.10 ± 0.03 1.17 ± 0.04O 
MA1 0.936 ± 0.087* 0.915 ± 0.071* 1.04 ± 0.09*S 0.993 ± 0.026* 1.04 ± 0.03*O 
RAL 0.981 ± 0.080*+ 1.09 ± 0.070*+ 1.10 ± 0.090*+S 1.09 ± 0.03+ 1.14 ± 0.05+O 
MA2 0.938 ± 0.059 0.993 ± 0.065 0.991 ± 0.051 1.14 ± 0.03 1.16 ± 0.03O 
ZOL 1.09 ± 0.08+ 0.987 ± 0.052S 1.01 ± 0.04S 1.20 ± 0.04+ 1.26 ± 0.04+O 
Mineral:Matrix  CONT 7.09 ± 0.41 7.99 ± 0.25S 8.27 ± 0.24S 8.74 ± 0.21 9.92 ± 0.26O  
MA1 7.17 ± 0.63 8.02 ± 0.37S 8.57 ± 0.32S 9.11 ± 0.20* 9.49 ± 0.21 
RAL 6.88 ± 0.59 7.94 ± 0.48S 7.77 ± 0.46S 9.23 ± 0.14* 9.99 ± 0.39O  
MA2 6.01 ± 0.30 7.03 ± 0.24S 7.48 ± 0.13SI 8.27 ± 0.15 9.23 ± 0.26O  
ZOL 6.64 ± 0.23+ 7.20 ± 0.21S 7.39 ± 0.17S 8.14 ± 0.12 9.60 ± 0.17*O 
B-Type Carbonate 
Substitution  
CONT 0.189 ± 0.005 0.200 ± 0.003S 0.199 ± 0.003S 0.202 ± 0.002 0.200 ± 0.002 
MA1 0.168 ± 0.007 0.178 ± 0.007S 0.187 ± 0.005SI 0.195 ± 0.002* 0.195 ± 0.003* 
RAL 0.163 ± 0.006 0.180 ± 0.006S 0.192 ± 0.006SI 0.200 ± 0.002+  0.192 ± 0.002*O  
MA2 0.185 ± 0.003 0.197 ± 0.004S 0.210 ± 0.003SI 0.202 ± 0.002 0.198 ± 0.002O  
ZOL 0.199 ± 0.004+ 0.205 ± 0.004+S 0.215 ± 0.004+SI 0.205 ± 0.002+  0.201 ± 0.001+O  
Crystallinity (cm-1)  CONT 0.0354 ± 
0.0011 
0.0365 ± 
0.0004S 
0.0362 ± 
0.0003S 
0.0374 ± 
0.0000 
0.0374 ± 
0.0001 
MA1 0.0358 ± 
0.0013 
0.0365 ± 
0.0006S 
0.0361 ± 
0.0005S 
0.0376 ± 
0.0001 
0.0373 ± 
0.0002O  
RAL 0.0358 ± 
0.0011 
0.0363 ± 
0.0008S 
0.0369 ± 
0.0008S 
0.0376 ± 
0.0001* 
0.0374 ± 
0.0001O  
MA2 0.0392 ± 
0.0005 
0.0390 ± 
0.0002S 
0.382 ± 0.0002SI 0.0375 ± 
0.0001 
0.0375 ± 
0.0001O  
ZOL 0.0390 ± 
0.0003+ 
0.0382 ± 
0.0005+S 
0.0378 ± 
0.0005+SI 
0.0374 ± 
0.0001+  
0.0373 ± 
0.0001+O  
Table 5.2 Absolute values for compositional and nanomechanical parameters by region in 
cancellous and cortical bone.  *Different from CONT 
+
Different from MA 
S
Different from 
Superficial, 
I
Different from Intermediate, 
O
Different from Osteonal 
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Despite the more modest gains in cortical tissue material properties, six months of 
zoledronate but not raloxifene improved bending stiffness in bulk tissue tests of cortical beams 
and improved bending stiffness and failure moment in whole bone tests.  The cortex of 
zoledronate treated sheep was larger in diameter (+28% cranial-caudal) and thicker (+14%) than 
that of the osteoporotic ewes, leading to an appreciably larger area moment of inertia.  However, 
variations between animals were large and the sample size underpowered for the whole-bone and 
bulk measures and these trends did not reach statistical significance.  
In both cancellous and cortical tissue, nanomechanical alterations with the osteoporotic 
model and treatment correlated with changes in tissue composition.  Cortical tissue 
mineralization, carbonate substitution into the mineral lattice, mineral crystal size and perfection, 
and lamellar aligned collagen content combined to explain nearly 50% of the variation in 
indentation modulus with the osteoporosis model and raloxifene treatment.  In cancellous tissue, 
carbonate substitution, crystal size and perfection, and aligned collagen explained 28% of the 
variations in indentation modulus with the ovine osteoporosis model and raloxifene treatment.  
B-type carbonate substitution was the strongest predictor of nanomechanical function in both the 
cortical and cancellous models.  Compositional parameters also correlated with nanomechanical 
variations due to the ovine osteoporosis model and zoledronate treatment; however, the 
explanatory power of the models was much more limited, 15% or less.  
The poor predictive power and the fact that many of the compositional relationships 
varied between treatment groups indicate that additional compositional factors not measured in 
these experiments also play a role in mechanical function with osteoporosis and treatment.  
These factors may include additional collagen cross-links not measured in these studies, mineral 
crystal orientation, and non-collagenous proteins, to name a few possibilities [28–30].  Advanced 
glycation end-product (AGE) accumulation has been observed with high doses of 
bisphosphonates in beagles [28].  AGEs form non-enzymatic collagen crosslinks (pentosidine, 
vesperlysine, and others) in bone and are associated with reduced post-yield work to fracture 
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[28].  Increases in these crosslinks, altered ratios of mature crosslinks (pyridinoline: 
deoxypridinoline), and altered ratios of native to isomerized collagen have also been noted with 
clinical doses of bisphosphonates in beagles [30].  Identifying relationships between these 
additional compositional factors and the nanomechanical behavior of bone tissue will provide a 
more complete picture of the manner by which composition ultimately determines mechanical 
function at the tissue level.  However, many of the current techniques for measuring these factors 
(x-ray diffraction, HPLC, and protein assays) require tissue homogenization or digestion and do 
not allow spatially-resolved measurements. 
  
5.3 Microcrack resistance 
Finally, a method was developed to directly test the ability of cortical bone tissue to resist 
microcracking.  Bisphosphonates have been linked with increased microcracking [23,31], and 
concern has arisen that excessive mineralization coupled with the reduced ability to repair 
microdamage with bisphosphonate treatment may promote the development and accumulation of 
microcracks [31,32].  Prior to the current work, a reliable method for directly testing the tissue-
level microcracking resistance of bone with disease and treatment had not been developed.  One 
previous study attempted to use indentation fracture to measure fracture toughness; however, 
samples were tested in a hydrated state and then dehydrated for imaging via SEM [33].  
Observations during sample preparation and the development of the current testing protocol 
suggest that cracks observed in the previous study likely did not result from indentation, but were 
formed during the subsequent dehydration of the tissue due to residual strain energy left in the 
samples from indentation.  Therefore, for the indentation fracture tests of this thesis, samples 
were dehydrated prior to testing and imaged pre and post-fracture so that measured cracks were 
guaranteed to be from the indentation fracture and not due to dehydration or cracks previously 
present in the sample.  Dehydration is known to increase tissue stiffness and hardness [34–36] 
and possibly could influence crack resistance; however, all samples were treated similarly and 
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therefore our ability to detect relative variations in these properties with osteoporosis and 
treatments was presumably not compromised. 
 With the newly-developed methods, six months of treatment with raloxifene and 
zoledronate in a model for human high-turnover osteoporosis did not affect the total amount of 
cracking present with indentation fracture, but did appear to affect cracking behavior.  The 
osteoporosis model had 45% longer crack length than healthy ewes, indicating that the cortical 
tissue was less able to withstand crack growth once microcracking was initiated.  These ewes 
also had reduced aligned collagen content, and collagen fiber bridging is a known toughening 
mechanism in bone that acts to prevent crack elongation [37].  Raloxifene treatment restored 
aligned collagen content to controls levels and concomitantly reduced the mean crack length due 
to indentation fracture.  In contrast to raloxifene, zoledronate did not alter cracking behavior 
relative to the osteoporosis model. Irrespective of treatment, interstitial cortical tissue that was 
more mineralized and harder than younger osteonal tissue had an increased propensity for 
cracking.  Interstitial tissue had greater numbers of cracks and greater crack length indicating an 
inferior resistance to both microcrack initiation and elongation.  This difference likely reflects 
the greater tissue age of interstitial relative to osteonal tissue.  Similar increases in tissue age and 
mineralization with the long-term suppression of remodeling with bisphosphonate treatment 
could result in tissue less able to prevent crack initiation and propagation.  The methods 
developed here can be used in future studies to investigate the effects of treatment duration 
(especially with longer-term treatment) on the ability of bone tissue to resist microcracking.   
 
5.4 Conclusions and Further Study 
 Based on the results from this thesis and evidence from previous studies, raloxifene 
normalizes bone tissue material properties to levels similar to those found in healthy animals.  
Here, raloxifene reversed degradations of tissue nanomechanical properties in cancellous and 
cortical tissue with a model for high-turnover osteoporosis and reversed the change in cortical 
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tissue’s resistance to microcrack elongation.  Raman compositional parameters and aligned 
collagen content with raloxifene treatment were also similar to those present in healthy ewes, 
with the exception of B-type carbonate substitution.  Differences in collagen crosslinking are 
present with bisphosphonates but not raloxifene relative to healthy animals [30].  Additionally, 
raloxifene normalized collagen crosslinks and restored toughness in cortical bone from a rabbit 
model with increased crosslinking from elevated homocystine levels [38].  These results suggest 
that raloxifene could potentially be used as a combination or sequential treatment with 
bisphosphonates to ameliorate bisphosphonate-induced alterations in tissue properties such as 
collagen crosslinking and microcrack accumulation.  Combination treatment with Alendronate 
and raloxifene previously improved femoral neck BMD more than either treatment alone, and 
raloxifene subsequent to Alendronate treatment preserved gains in BMD in the spine and femoral 
neck [39].  Thus, combining bisphosphonate and SERM treatment either together or in 
succession could potentially combine the best aspects of both treatments—the ability to quickly 
improve strength and stiffness on active bone surfaces provided by zoledronate, followed by 
normalization of the material properties throughout the tissue provided by raloxifene.  The 
methods presented in the current thesis can also be applied to these combined or sequential 
treatments to validate these hypotheses. 
 A considerable limitation of the ovine studies was that the sheep were estrogen replete, 
unlike women with post-menopausal osteoporosis.  Circulating estrogen could blunt the effects 
of raloxifene treatment because both estrogen and SERMs act through estrogen receptor 
pathways.  Another limitation was that cancellous and cortical strength was not reduced with six 
months of the metabolic acidosis model, as in a previous study of this model [40–42].  The 
researchers who developed the ovine MA model have also developed a combined OVX and 
metabolic acidosis to produce greater reductions in turnover and BMD [42,43].  Future use of 
this improved model would not only ensure that ewes are sufficiently osteopenic, but would also 
allow study of raloxifene with estrogen deficiency.   
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 A limitation of the indentation fracture experiments developed in this thesis was that 
SEM imaging allows visualizes surface cracks and does not enable analysis of sub-surface 
damage or cracks deflected in the longitudinal direction of the bone.  Future study of 
longitudinally oriented samples would allow crack propagation in the longitudinal direction to be 
examined.  In addition, indentation fracture could be performed in hydrated bone, with pre-and 
post- staining (calcein, xylenol orange, or some other fluorochrome) to visualize damage and 
microcracking below the sample surface with confocal microscopy.  The two-photon imaging 
system used for SHG in this thesis work can visualize microcracks stained with fluorescence up 
to 60-100 µm below the surface.  Stacks of images (z-stacks) could then be used to build a three-
dimensional image of cracking from indentation fracture tests and compare the complete amount 
of cracking and microcrack morphology in healthy, osteoporotic, and treated tissue.  The two-
photon system also has the ability to image different wavelengths in different channels 
simultaneously, allowing co-localized images of the collagen alignment and orientation to be 
collected with SHG to examine direct relationships between collagen structure and microcrack 
formation and propagation.  Combination of these techniques with vibrational spectroscopy to 
measure tissue composition at indentation fractured locations could allow examination of the 
contribution of compositional parameters to crack initiation and crack elongation. 
Finally, indentation of interstitial bone tissue near cement lines could be used to examine 
the interactions between cracks and these features known to be crucial for crack deflection and 
arrest in cortical bone [44–46].  These experiments could investigate the effects of osteoporosis 
and treatment induced alterations on crack behavior at cement lines (arrest, deflection or 
propagation) and determine whether this behavior is affected by the changes in relative osteonal 
to interstitial moduli observed in the current thesis work.  Also, combining these tests with 
spectroscopic compositional measurements of the cement lines, themselves, could determine the 
effects of cement-line composition and collagen alignment on the manner in which cracks 
interact with these interfaces (and the effects of antiresorptive treatment).     
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 The size of the indentations required for the fracture tests of this thesis preclude 
examination of cancellous bone because insufficient tissue exists subsurface in the trabeculae to 
support these large indentations.  Previously, bending, tension, and buckling tests have been 
performed on single excised trabeculae [47–50].  A similar approach paired with the 
aforementioned confocal imaging techniques could determine differences in microcrack 
resistance and morphology in cancellous tissue with osteoporosis and treatments.  Bending tests 
of single trabeculae could also determine if the improvements in estimated bending stiffness with 
raloxifene and zoledronate observed in this thesis hold true experimentally. 
 
5.5 Extended Application– Increased Fracture Risk with Diabetes Mellitus 
The techniques presented in this thesis along with the proposed future techniques for three 
dimensional imaging of microcracking behavior in bone tissue can be used to examine 
compositional alterations with other pathological skeletal conditions and determine the resulting 
effects on tissue nanomechanical properties and microcracking resistance.  A particularly 
interesting and clinically important direction is the study of increased fracture risk due to 
diabetes mellitus. 
Like osteoporosis, diabetes presents an increasing health and economic burden in the 
United States and throughout the world [51,52].  Interestingly, fracture risk increases in patients 
with both type-1 (diabetes mellitus 1, DM1) and type-2 diabetes (diabetes mellitus 2, DM2), 
although only DM1 is associated with a decrease in BMD [51,53–55].  At least 50% of patients 
with DM1 are estimated to have bone loss, and 20% of patients aged 20-56 have BMD t-scores 
less than the -2.5 defined as osteoporotic [52].  The decrease in BMD is associated with a 1-2 
fold increase in fracture risk at the spine, 1.5-2.5 increase at the hip, and 2-fold increase at the 
radius [52].  A meta-analysis of 5 studies with fracture data show a much higher absolute risk for 
fracture at the hip than would be calculated based on BMD measurements, suggesting that 
alterations in micro- and nanoscale tissue properties may play a factor [52].  Even more 
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perplexing are the increases in fracture risk with DM2 that occur despite higher or normal BMD 
even after correcting for increased body size due to obesity [51,53,54]. 
The exact mechanisms for bone fragility in diabetes are not known and may differ 
between DM1 and DM2.  Experimental and clinical evidence suggest that diabetes-associated 
bone abnormalities may differ from those in senile or post-menopausal osteoporosis [52].  Both 
DM1 and DM2 demonstrate remodeling imbalances.  DM1 predominantly decreases formation 
due to a reduction in insulin production (insulin has anabolic effects in bone) [51,53,54], whereas 
DM2 both increases resorption and decreases formation [51,53,54].  These remodeling 
imbalances and effects of hyperglycemia in both DM1 and DM2 can alter tissue material 
properties and distributions of these properties within bone tissue that cannot be captured by 
BMD measurements and may explain the discrepancies between variations in BMD and fracture 
risk.  Hyperglycemia can affect the skeleton through a variety of mechanisms and so far has been 
shown to increase the formation of advanced glycation end-products (through non-enzymatic 
glycation), resulting in increased detrimental collagen crosslinks in bone [52,56].  
To date, few studies have examined tissue-level alterations with diabetes, and have 
focused on non-spatially specific changes in the levels AGEs and resulting collagen crosslinks 
[52,53,56].  A single study has examined alterations in tissue nanomechanical properties with 
DM1, yet no study has directly examined effects of changes in tissue mineral and matrix 
composition with diabetes on the tissue-level nanomechanical function or crack resistance of 
bone tissue [57].  In the osteoporosis literature, AGE accumulation with bisphosphonate 
treatment was associated with decreased post-yield work to fracture and increased microdamage 
in beagles [28].  Like bisphosphonates, low turnover sites with DM2 are particularly prone to 
AGE and microdamage accumulation [52].  Indeed, diabetic patients with fracture exhibit 
increased levels of pentosidine crosslinks. 
 The techniques presented in this thesis along with the proposed future techniques for 
three dimensional imaging of microcrack behavior in cortical and cancellous bone can be used to 
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document spatially-specific compositional alterations with DM1 and DM2 and the resulting 
effects on tissue nanomechanical properties and microcracking resistance.  Combining these 
studies with examination of diabetic bone at higher length scales (bulk and whole bone 
architecture and mechanical performance) can determine the mechanisms of skeletal fragility 
with diabetes.  As diabetes is a complex disorder, rodent models can first be used to determine 
the effects of individual components such as insulin resistance, hyperglycemia, diabetic 
complications (kidney disease, renal failure), etc., individually, on bone material properties and 
mechanical behavior [52,53,58,59].  Subsequently, studies using larger animal models such as 
the New Zealand white rabbit or keeshond dog for DM1, and the streptozotocin-treated pig for 
DM2, can be utilized to determine the spatial variations of tissue material properties with 
diabetes in animals with similar Haversian microstructures to those of human bone [59]. 
 Finally, many diabetic drug treatments have direct effects on bone and may impact 
fracture resistance.  The thiazolidinediones (TZDs) decrease osteoblast differentiation and are 
associated with bone loss and a higher risk for fracture, particularly in females [52].  The skeletal 
effects of other classes of drugs are less documented, although patients treated with metformin or 
sulfonylurea may have reduced fracture risk due to positive effects on osteoblast differentiation 
and activity [52].  Similar to the aims for this thesis, determining the relationships between tissue 
material properties, microcracking resistance, and mechanical performance at higher length 
scales with diabetes and treatments will enable a better understanding of normal and pathological 
bone function with this disease and may support the development of new and improved therapies 
for prevention and treatment.   
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A         B 
Figure A1  (A) Cortical thickness, (B) cranial-caudal diameter, (C) medial-lateral diameter, 
and (D) area of mid-diaphyseal sections.  No differences were found between treatment 
groups due to relatively large variations between sheep. 
C         D 
APPENDIX 
ADDITIONAL OVINE CORTICAL DATA AND FIGURES 
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A         B 
Figure A2  (A) Number of cracks and (B) maximum crack length due to indentation fracture 
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      Before             After 
Figure A3  Representative SEM images taken before and after indentation fracture in 
osteons of cortical bone from Control (normal diet) sheep.   
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      Before             After 
Figure A4  Representative SEM images taken before and after indentation fracture in 
osteons of cortical bone from MA1 sheep.   
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      Before             After 
Figure A5  Representative SEM images taken before and after indentation fracture in 
osteons of cortical bone from raloxifene treated sheep.   
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      Before             After 
Figure A6  Representative SEM images taken before and after indentation fracture in 
osteons of cortical bone from MA2 sheep.   
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      Before             After 
Figure A7 Representative SEM images taken before and after indentation fracture in 
osteons of cortical bone from zoledronate treated sheep.   
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      Before             After 
Figure A8 Representative SEM images taken before and after indentation fracture in 
interstitial tissue of cortical bone from Control (normal diet) sheep.   
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      Before             After 
Figure A9 Representative SEM images taken before and after indentation fracture in 
interstitial tissue of cortical bone from MA1 sheep.   
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      Before             After 
Figure A10 Representative SEM images taken before and after indentation fracture in 
interstitial tissue of cortical bone from raloxifene treated sheep.   
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      Before             After 
Figure A11 Representative SEM images taken before and after indentation fracture in 
interstitial tissue of cortical bone from MA2 sheep.   
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      Before             After 
Figure A12  Representative SEM images taken before and after indentation fracture in 
interstitial tissue of cortical bone from zoledronate treated sheep.   
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